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µm Micrometer
µl Micro liter
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INTRODUCTION
Oral route of drug administration is most appealing route for delivery of
drugs of various dosage forms. The tablets is one of the most preferred dosage form
because of its ease of administration, accurate dosing and stability as compared to
oral liquid dosage forms and when compared to capsules, tablets are more temper
evident
1.1 TABLETS1
Tablets  may  be  defined  as  solid  unit  pharmaceutical  dosage  forms
containing drug substance with or without suitable Excipients and prepared by either
compression or molding mehtods1. The first step in the development of dosage form
is  Preformulation,  which  can  be  defined  as  investigation  of  physicochemical
properties of drug substance alone and when combined with Excipients. The main
objective of Preformulation studies, is to develop stable and bioavilabel dosage form
and study of factors affecting such stability, bioavailability and to optimize so as to
formulate the best dosage form, here optimization of formulation means finding the
best possible composition2.  compressed tablets are formed by applying pressure, for
which  compression  machines  (tablet  presses)  are  used  and  they  are  made  from
powdered  crystalline  or  granular  material,  alone  or  in  combination  with  binder,
disintegrants, release polymers, lubricants and diluents and in some cases colorant.
1.1.1 Various Types of Tablets2
A. Oral tablets for ingestion
These tablets  are  meant  to  be  swallowed intact  along with a  sufficient
quantity of potable water.  Exception is chewable tablet.  Over 90% of the tablets
manufactured today are ingested orally. This shows that this class of formulation is
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the most popular worldwide and the major attention of the researcher is towards this
direction.
1. Standard compressed tablets
2 Multiple compressed tablets
a. Compression coated tablet
b. Layered tablet
c. Inlay tablet
3. Modified Release tablet
4. Delayed action tablet
5. Targeted tablet
a. Floating tablet
b. Colon targeting tablet
6. Chewable tablet
7. Dispersible tablet
B. Tablets used in the oral cavity
The  tablets  under  this  group  are  aimed  release  active  pharmaceutical
ingredient in oral cavity or to provide local action in this region. The tablets under
this category avoids first-pass metabolism, decomposition in gastric environment,
nauseatic sensations and gives rapid onset of action. The tablets formulated for this
region are designed to fit in proper region of oral cavity.
1. Lozenges and troches
2. Sublingual tablet
3. Buccal tablet
4. Dental cones
5. Mouth dissolved tablet
2
C. Tablets administered by other routes
These tablets are administered by other route except for the oral cavity and
so the drugs are avoided from passing through gastro intestinal tract. These tablets
may be inserted into other  body cavities or directly placed below the skin to be
absorbed into systemic circulation from the site of application.
1. Vaginal tablet
2. Implants
D. Tablets used to prepare solution
The tablets under this category are required to be dissolved first in water or
other  solvents  before  administration  or  application.  This  solution  may  be  for
ingestion  or  parentral  application  or  for  topical  use  depending  upon  type  of
medicament used.
1. Effervescent tablet
2. Hypodermic tablet
1.2 FORMULATION OF TABLETS
In addition to active pharmaceutical agent (API), the tablets contain non
drug substances called as Excipients, which include:
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Table-1 Excipients in Tablet Formulation and Their Functions2,3
Diluents or Fillers         Diluents make the required bulk of the tablet when the
drug dosage itself is inadequate to produce tablets of
adequate weight and size.
Binders/ Granulating  agents Provides cohesiveness to powders, thus providing the
necessary bonding to form granules.
Disintegrates                   Facilitate  a  breakup  or  disintegration  of  the  tablet
when placed in an aqueous environment.
Antifrictional Agents
Lubricants         Reduce the friction during tablet  formation in a  die
and also during ejection from die cavity.
Anti adherents                 Reduce  sticking  or  adhesion  of  any  of  the  tablet
granulation or powder to the faces of the punches or to
the die wall.
Glidants                          Promote  the  flow  of  tablet  granulation  or  powder
mixture  from hopper  to  the  die  cavity  by  reducing
friction between the particles.
Miscellaneous
Wetting agents               Aid water uptake during disintegration and assist drug
dissolution.
Dissolution retardants    Retards  the  dissolution  of  active  pharmaceutical
ingredients.
Dissolution enhancers    Enhance the dissolution rate of active pharmaceutical
ingredients.
Adsorbents                     Retain  large  quantities  of  liquids  without  becoming
wet; this property allows many oils, fluid extracts to
be incorporated into tablets.
Buffers                           Provide  suitable  micro  environmental  pH  to  get
improved stability and / or bioavailability.
Antioxidants                   Prevents oxidation and maintains the product stability.
Chelating agents             Protect  against  autoxidation;  they  act  by  forming
complexes with the heavy metal ions which are often
required to initiate oxidative reactions.
Preservatives                   Prevent the growth of micro-organisms.
Colors & flavors          Provides  attractiveness,  increase  patient  compliance
and product identification. 
Sweeteners                       Sweeteners are added to mask bitter taste of tablets
1.3 TABLET: MANUFACTURING METHODS2, 3, 4
4
1.3.1 Wet Granulation
The most widely used process of agglomeration in pharmaceutical industry
is  wet  granulation.  Wet  granulation  process  simply involves  wet  massing of  the
powder blend with a granulating liquid, wet sizing, drying and compression.
Raw materials  →  Weighing →  Screening →  Wet  mass  →  Sieving/Milling →
Drying → Screening → Mixing → Compression
1.3.2 Dry Granulation
In dry granulation process the powder mixture is compressed without the
use of heat and solvent. Two methods are used for dry granulation. The more widely
used  method is  slugging,  where  the powder  is  pre  compressed  and the resulting
tablet or slug are milled to yield the granules and the compressed to tablets.
Raw  material  →  Weighing  →  Screen  →  Mixing  →  Slugging  →Milling  →
Screening → Mixing → Compression                                                             
1.3.3 Direct Compression
Direct  compression  is  a  more  efficient  and  economical  process  as
compared to other processes, because it involves only dry blending and compaction
of API and necessary excipients.
Raw material →Weighing → Screening → Mixing → Compression
1.3.4 Defects in Tablet Manufacturing 2, 3
 Lamination:  Separation  of  a  tablet  into  two  or  more  distinct
horizontal layers.
 Capping: Partial or complete separation of top or bottom crowns of a
tablet.
 Chipping: Breaking of tablet edges during compression or coating.
5
 Cracking:  Fine  cracks  observed  on  the  upper  and  lower  central
surface of tablets, or very rarely on the sidewall are referred to as
‘Cracks’.
 Picking:  In picking the tablet material adheres to the surface of the
punches resulting in tablets with a pitted surface instead of a smooth
surface.
 Sticking: The tablet material adheres to the die wall.
 Mottling: Unequal distribution of colour on the surface of coloured
tablets.
 Blotting:  Appearance of light or dark spots of colour on the tablet
surface.
 Double Impression:  It  involves only those punches, which have a
monogram or other engraving on them. Free travel or free rotation of
either upper punch or lower punch during ejection of a tablet causes
double impression.                        
1.4 ORAL DISINTEGRATING TABLETS
The most important drug delivery route is undoubtedly the oral route. It
offers advantages of convenience of administration and potential manufacturing cost
savings. Drugs that are administered orally, solid oral dosage forms in general and
tablets in particular represent the preferred class of product. Today drug delivery
companies are focusing on solid oral drug delivery systems that offer greater patient
compliance  and  effective  dosages.  Tablet  is  the  most  popular  among all  dosage
forms existing today because of its convenience of self administration, compactness
and easy manufacturing. Many patients find it difficult to swallow tablets and hard
gelatin  capsules  and  do  not  take  their  medication  as  prescribed.  In  a  survey
conducted by Honda and Nakano, half of the patients experienced difficulty taking
medication, such as tablet and capsule which results  in a high incidence of non-
compliance and ineffective therapy.  The difficulty is experienced in particular by
paediatric and geriatric patients, but it also applies to people who are ill in bed and
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to those active working patients who are busy or traveling,  especially those who
have no access  to water.5 Over  a decade,  the demand for  development  of orally
disintegrating tablets (ODTs) has enormously increased as it has significant impact
on  the  patient  compliance.  Orally  disintegrating  tablets  offer  an  advantage  for
populations who have difficulty in swallowing. It has been reported that Dysphagia
(difficulty in swallowing) is common among all age groups and more specific with
pediatric, geriatric population along with institutionalized patients and patients with
nausea,  vomiting, and motion sickness complications. ODTs with good taste and
flavor increase  the acceptability of bitter  drugs by various  groups of population.
Orally  disintegrating  tablets  are  also  called  as  orodispersible  tablets,  quick
disintegrating  tablets,  mouth  dissolving  tablets,  fast  disintegrating  tablets,  fast
dissolving tablets, rapid dissolving tablets, porous tablets, and rapimelts. However,
of all the above terms, United States pharmacopoeia (USP) approved these dosage
forms  as  ODTs.  Recently,  European  Pharmacopoeia  has  used  the  term
orodispersible tablet for tablets that disperses readily and within 3 min in mouth
before  swallowing.  United  States  Food and  Drug Administration (FDA)  defined
ODT as “A solid dosage form containing medicinal substance or active ingredient
which disintegrates rapidly usually within a matter of seconds when placed upon the
tongue.” The disintegration time for ODTs generally ranges from several seconds to
about a minute6.
1.4.1 Historical Perspective of ODT
Products  of  ODT technologies  entered  the  market  in  the  1980’s,  have
grown steadily in demand, and their product pipelines are rapidly expanding. The
first ODT form of a drug to get approval from the US (FDA) was a Zydis ODT of
Claritin  (Loratadine)  in  December  1996.  It  was  followed  by  a  ZYDIS  ODT
formulation  of  Klonopin  (Clonazepam)  in  December  1997,  and  a  ZYDIS  ODT
formulation  of  Maxalt  (Rizatriptan)  in  June  1998.  CATALENT  PHARMA
SOLUTIONS in the U.K., CIMA LABS in the U.S. and TAKEDA Pharmaceutical
Company in Japan lead in the development of ODTs7. 
Consumer Preferences for ODT’s8
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Recent market studies indicate that most of the patient population prefers
ODTs to other dosage forms and would ask their doctors for ODTs (70%), purchase
ODTs (70%),  or  prefer  ODTs  to  regular  tablets  or  liquids  (>80%).  In  addition,
several  business  needs  are  driving  ODT  technology  development  and  the
commercialization of new products such as the need for expanded product lines,
improved life-cycle management, extended patent life, and marketing advantages7,8.
               
Figure-1 consumer’s response on ODT’s
1.4.2 Drug Selection Criteria
The ideal characteristics of a drug for orodispersible tablet include 9
• Ability to permeate the oral mucosa.
• At least partially non-ionized at the oral cavity pH.
• Have the ability to diffuse and partition into the epithelium of the upper
GIT.
• Small to moderate molecular weight.
• Low dose drugs preferably less than 50 mg.
• Short half life and frequent dosing drugs are unsuitable for ODT.
• Drug should have good stability in saliva and water.
• Very bitter or unacceptable taste and odour drugs are unsuitable for ODT.
1.4.3 Important Criteria for Excipients used in the Formulation of ODT’S
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• It must be able to disintegrate quickly.
• Their individual properties should not affect the ODTs.
• It should not have any interactions with drug and other excipients.
• It should not interfere in the efficacy and organoleptic properties of
the product.
• When selecting binder a (single or combination of binders) care must
be taken in the final integrity and stability of the product.
• The melting points  of  excipients  used will  be in  the range  of  30-
350C.
• The  binders  may  be  in  liquid,  semi  liquid,  solid  or  polymeric
mixtures10.
• (Ex: Polyethylene glycol, cocoa butter, hydrogenated vegetable oils)
1.4.4 Advantages 11, 12
• Easy  to  administer  to  the  patient  who  cannot  swallow  such  as
pediatric,  geriatric,  bedridden,  stroke  victim  and  institutionalized
patient ( specially for mentally retarded and psychiatric patients)
• Pregastric  absorption  leading  to  increased  bioavaibility  rapid
absorption of drugs from mouth, pharynx and oesophagus as saliva
passes down to stomach, also avoids hepatic metabolism.
• Convenient for administration to travelling patients and busy people
who do not have accesses to water.
• Excellent  mouths  feel  property  produced  by  use  of  flavours  and
sweetners help to change the perception of “medication as bitter pill”
especially in pediatric population.
• Fast  disintegration  of  tablets  leads  to  quick  dissolution  and  rapid
absorption which may produce rapid onset of action.
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• ODTs  offer  all  the  advantages  of  solid  dosage  forms  and  liquid
dosage forms.
• Convenience  of  administration  and  accurate  dosing  compared  to
liquids.
1.4.5 Challenges in the Formulation of Orally Disintegrating Tablets
Palatability13, 14
As most drugs are unpalatable, orally disintegrating drug delivery systems
usually  contain  the  medicament  in  a  taste-masked  form.  Delivery  systems
disintegrate or dissolve in patient’s oral cavity, thus releasing the active ingredients
which  come  in  contact  with  the  taste  buds;  hence,  taste-masking  of  the  drugs
becomes critical to patient compliance
Mechanical strength15, 16, 17
In order to allow ODTs to disintegrate in the oral cavity, they are made of
either very porous and soft-molded matrices or compressed into tablets with very
low compression force,  which makes the tablets friable and/or brittle, difficult to
handle, and often requiring specialized peel-off blister packing that may add to the
cost.  Only  few  technologies  can  produce  tablets  that  are  sufficiently  hard  and
durable to allow them to be packaged in multidose bottles, such as Wowtab® by
Yamanouchi-Shaklee, and Durasolv® by CIMA labs.
Hygroscopicity18
Several  orally  disintegrating  dosage  forms  are  hygroscopic  and  cannot
maintain physical integrity under normal conditions of temperature and humidity.
Hence,  they  need  protection  from  humidity  which  calls  for  specialized  product
packaging
Amount of drug13, 19
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The application of technologies used for ODTs is limited by the amount of
drug that can be incorporated into each unit dose. For lyophilized dosage forms, the
drug dose must be lower than 400 mg for insoluble drugs and less than 60 mg for
soluble drugs. This parameter is particularly challenging when formulating a fast-
dissolving oral films or wafers.
Aqueous solubility20, 21
Water-soluble  drugs  pose  various  formulation  challenges  because  they
form eutectic mixtures, which result in freezing-point depression and the formation
of  a  glassy  solid  that  may  collapse  upon  drying  because  of  loss  of  supporting
structure during the sublimation process. Such collapse sometimes can be prevented
by  using  various  matrix-forming  excipients  such  as  Mannitol  than  can  induce
crystallinity and hence, impart rigidity to the amorphous composite.
Size of tablet22
The degree of ease when taking a tablet depends on its size. It has been
reported that the easiest size of tablet to swallow is 7-8 mm while the easiest size to
handle was one larger than 8 mm. Therefore, the tablet size that is both easy to take
and easy to handle is difficult to achieve.
Table-2 Drugs Explored for Orally Disintegrating Tablets.23
Category Drug
NSAIDS Ketoprofen, Piroxicam, Paracetomol, Rofecoxib, Nimesulide,Ibuprofen
Anti ulcer Famotidine, Lansoprazole
Anti parkinsonism Selegiline
Anti depressants Mitraxepine, Fluoxetine, Escitalopram Oxalate
Anti migrane Sumatriptan, Rizatriptan benzoate, Zolmitriptan
Anti histaminics Loratadine, Diphenhydramine, Meclizine
Hypnotics sedatives Zolpidem, Clonazepam, Atenolol
Anti psychotics Olanzepine, Pirenzepine, Risperidone
Anti emetics Ramosetoron HCl, Ondansetron
Miscellaneous Ethenzamide,  Baclofen,  Hydrochlorthiazide,  Tramodol  Hcl,Propyphenazone,   Spiranolactone,   Phloroglucinol, Sildenafil
1.5 VARIOUS APPROACHES EMPLOYED IN MANUFACTURE OF  
ODT’S
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There are number of techniques generally employed in the formulation of
orally disintegrating dosage forms. These techniques have their own advantages as
well as disadvantages and are described below:
1.5.1 Direct Compression
Direct  compression is  one of  the popular  techniques  for  preparation  of
these dosage forms. The advantages of this method include easy implementation,
use of conventional equipments along with commonly available excipients, limited
number of processing steps and cost effectiveness. Disintegration and solubilization
of directly compressed tablets depend on single or combined action of disintegrants,
water-soluble excipients and effervescent  agents.  The basic principle involved in
development  of  these  dosage  forms  using  this  technique  is  addition  of
Superdisintegrants in optimum concentrations so as to achieve rapid disintegration
along with pleasant mouth feel  24. It  is considered as the best method to prepare
orally  disintegrating  dosage  forms  since  the  prepared  tablets  offer  higher
disintegration due to absence of binder and low moisture contents 25. This approach
is also considered as disintegrant addition technology. 
1.5.2 Freeze Drying
Freeze drying or lyophilization is a process in which solvent is removed
from a frozen drug solution or suspension containing structure forming excipients.
Tablets formulated by this technique are usually very light  and porous in nature
which  allows  their  rapid  dissolution.  Glassy  amorphous  porous  structure  of
excipients  as  well  as  the  drug substance  produced  with  freeze  drying  results  in
enhanced dissolution. Freeze drying process normally consists of three steps:
• Material is frozen to bring it below the eutectic point.
• Primary drying to reduce the moisture around 4% w/w of dry product.
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• Secondary  drying  to  reduce  the  bound  moisture  upto  required  final
volume.
Entire  freeze drying process  is  carried out  at  non elevated temperature;
therefore,  nullifying adverse thermal  effects  that  may affect  drug stability during
processing24.  R.P.  Scherer  patented  zydis  technology  utilizing  lyophilization  or
freeze drying process in development of mouth dissolving tablets on the basis of
patents  issued  to  Gregory  et  al 26,27.  Corveleyn  Sam  et  al  also  prepared  rapidly
disintegrating tablets by lyophilization 28.
1.5.3 Sublimation
Because  of  low  porosity,  compressed  tablets  containing  highly  water-
soluble excipients as tablet matrix material often do not dissolve rapidly in water.
Some  inert  volatile  substances  like  urea,  urethane,  ammonium  carbonate,
naphthalene,  camphor  etc.  are  added  to  other  tablet  excipients  and  blend  is
compressed into tablet. Removal of volatile substances by sublimation generates a
porous structure. Various steps involved in sublimation process are shown in Figure
1. Additionally several solvents like cyclohexane and benzene etc. can also be used
as pore forming agents.
                                           
Figure 2: Steps involved in sublimation process
Koizumi et al  formulated rapidly saliva soluble tablets using camphor as
subliming  agent.  The  tablets  were  subjected  to  vacuum  at  80ºC for  30  min.  to
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eliminate camphor and thus create pores in the tablet. Porous tablet exhibits good
mechanical  strength  and  dissolve  quickly29.  Gohel  M.  et  al  prepared  mouth
dissolving tablets of nimesulide using vacuum drying technique and found that it
would be an effective alternative approach compared to the use of more expensive
adjuvants in the formulation of these dosage forms 30
1.5.4 Moulding
Moulded  tablets  are  designed  to  facilitate  the  absorption  of  active
ingredients through mucosal  linings of mouth. This is  achieved by complete and
rapid  dissolution  of  the  tablet  using  water  soluble  ingredients.  Moulded  tablets
disintegrate more rapidly and offer improved taste because of the dispersion matrix
which is generally prepared from water soluble sugars. Powdered blend (containing
drug  and  excipients  like  binding  agents  -  sucrose,  acacia,  PVP  etc.)  is  pushed
through a very fine screen (to ensure rapid dissolution) and then moistened with a
hydroalcoholic  solvent  and  moulded  into  tablets  under  pressure  lower  than
employed for conventional compressed tablets. The solvent is later removed by air
drying. A porous structure that enhances dissolution prepared by using water soluble
ingredients meant to be absorbed through mucosal lining of mouth, thus increasing
bioavailability and decreasing first pass metabolism of certain drugs. 
1.5.5 Spray Drying
This  technique  is  based  upon  the  use  of  a  particulate  support  matrix
prepared by spray drying an aqueous composition containing support  matrix  and
other components to form a highly porous and fine powder. Allen et al utilized this
process  for  preparing  ODTs.  These  formulations  consisted  of
hydrolyzed/unhydrolyzed gelatin as supporting agent for matrix, mannitol as bulking
agent, and sodium starch glycolate or croscarmellose sodium as disintegrating agent.
Disintegration  and  dissolution  were  further  improved  by  adding  effervescent
components, i.e. citric acid and sodium bicarbonate.  The formulation was finally
spray dried to yield a porous powder 31.
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1.5.6 Mass Extrusion
This  technology  consist  of  softening  the  active  blend  using  a  solvent
mixture  of  water  soluble  Polyethylene  glycol  with  methanol  and  expulsion  of
softened mass through the extruder or syringe to obtain cylinder of the product into
even segments employing heated blade to form tablet. The dried cylinder can also be
utilized for coating the granules of bitter drugs and there by masking their taste31,32 
1.5.7 Cotton Candy Process
This process is so named as it utilizes an inimitable spinning mechanism to
produce floss like crystalline structure, which mimics cotton candy. This technique
involves  formation  of  matrix  of  polysaccharides  or  saccharides  by  simultaneous
action of flash melting and spinning. The matrix formed is partially recrystallized to
have better flow properties and compressibility. This matrix is milled and blended
with active ingredients as well as excipients and subsequently compressed to ODTs.
This process can accommodate high doses of drug and offers improved mechanical
strength. However, high process temperature limits the use of this process31.
1.5.8 Phase Transition
Kuno  etal  proposed  a  novel  method  to  prepare  ODTs  with  sufficient
hardness by involving the phase transition of sugar alcohol. In this technique, ODTs
are  produced  by  compressing  and  subsequently  heating  tablets  that  contain  two
sugar alcohols, one with high and other with a low melting point. Heating process
enhances  the  bonding  among  particles  leading  to  sufficient  Hardness  of  tablets
which was otherwise lacking owing to low/little compatibility 33.
1.5.9 Melt Granulation
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Melt  granulation  is  a  process  in  which  pharmaceutical  powders  are
efficiently agglomerated by the use of binder which can be a molten liquid, a solid
or a solid that melts during the process. For accomplishing this process, high shear
mixers are utilized, where the product temperature is raised above the melting point
of binder by a heating jacket or by the heat of friction generated by impeller blades.
Perissutti  et  al  prepared  carbamazepine  fast-release  tablets  by  melt  granulation
technique  using  polyethylene  glycol  4000  as  a  melting  binder  and  lactose
monohydrate as hydrophilic filler 34, 35.
1.6 IMPORTANT  PATENTED  TECHNOLOGIES  FOR  FAST  
DISSOLVING TABLETS36-40
Zydis Technology
Zydis  formulation  is  a  unique  freeze  dried  tablet  in  which  drug  is
physically  entrapped  or  dissolved  within  the  matrix  of  fast  dissolving  carrier
material.  When  zydis  units  are  put  into  the  mouth,  the  freeze-dried  structure
disintegrates  instantaneously  and  does  not  require  water  to  aid  swallowing.  The
zydis  matrix  is  composed  of  many  material  designed  to  achieve  a  number  of
objectives.  To  impart  strength  and  resilience  during  handling,  polymers  such  as
gelatin,  dextran  or  alginates  are  incorporated.  These  form  a  glossy  amorphous
structure,  which imparts  strength.  To obtain crystallinity,  elegance  and hardness,
saccharides  such  as  mannitol  or  sorbitol  are  incorporated.  Water  is  used  in  the
manufacturing  process  to  ensure  production  of  porous  units  to  achieve  rapid
disintegration while various gums are used to prevent sedimentation of dispersed
drug particles in the manufacturing process.
Durasolv Technology
Durasolv is the patented technology of CIMA labs. The tablets made by
this technology consist of drug, filler and a lubricant. Tablets are prepared by using
conventional tabulating equipment and have good rigidity. These can be packaged
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into  conventional  packaging  system  like  blisters.  Durasolv  is  an  appropriate
technology for product requiring low amounts of active ingredients.
Orasolv Technology
CIMA labs  have  developed  Orasolv  Technology.  In  this  system active
medicament  is  taste  masked.  It  also  contains  effervescent  disintegrating  agent.
Tablets are made by direct compression technique at low compression force in order
to minimize oral dissolution time. Conventional blenders and tablet machine is used
to produce the tablets. The tablets produced are soft and friable.
Flash Dose Technology
Flash dose technology has been patented by fuisz. Nurofen meltlet, a new
form of ibuprofen as melt in mouth tablets prepared using flash dose technology is
the first commercial  product launched by Biovail Corporation. Flash dose tablets
consist of self-binding shear form matrix termed as “floss”. Shear form matrices are
prepared by flash heat processing.
Wow tab Technology
Wow  tab  technology  is  patented  by  Yamanouchi  Pharmaceutical
Co.WOW  means  “Without  Water”.  In  this  process,  combination  of  low  mould
ability saccharides and high mould ability saccharides is used to obtain a rapidly
melting  strong  tablet.  The  active  ingredient  is  mixed  with  a  low mould  ability
saccharide (eg. lactose, glucose, and mannitol) and granulated with a high mould
ability saccharide (eg. Maltose, oligosaccharides) and compressed into tablet.
Flash tab Technology
Prographarm laboratories have patented the Flash tab technology. Tablet
prepared  by  this  system  consists  of  an  active  ingredient  in  the  form  of  micro
crystals. Drug micro granules may be prepared by using the conventional techniques
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like   coacervation,  micro  encapsulation  and  extrusion  spheronisation.  All  the
processing utilized conventional tabletting technology.
OraQuick
The OraQuick  fast-dissolving/disintegrating tablet  formulation utilizes a
patent  taste  masking  technology.  KV  Pharmaceutical  claims  its  microsphere
technology,  known  as  MicroMask,  has  superior  mouthfeel  over  taste-masking
alternatives. The taste masking process does not utilize solvents of any kind, and
therefore leads to faster and more efficient production.
Quick –Dis Technology
Lavipharm Laboratories Inc. (Lavipharm) has invented an ideal intraoral
fast-dissolving drug delivery system, which satisfies the unmet needs of the market.
The novel intraoral drug delivery system, trademarked Quick- Dis™, is Lavipharm’s
proprietary patented technology and is a thin, flexible, and quick-dissolving film.
The film is placed on the top or the floor of the tongue. It is retained at the site of
application  and  rapidly  releases  the  active  agent  for  local  and/or  systemic
absorption.  The  Quick-Dis™  drug  delivery  system  can  be  provided  in  various
packaging configurations, ranging from unit dose pouches to multiple-dose blister
packages. The typical disintegration time, which is defined as the time at which the
film begins to break when brought into contact with water, is only 5 to 10 seconds
for the Quick- Dis™ film with a thickness of 2 mm. drug delivery system is 50%
released within 30 seconds and 95% within 1 minute.
Durasolv Technology
DuraSolv is Cima’s second-generation fast-dissolving/disintegrating tablet
formulation. Produced in a fashion similar to OraSolv, DuraSolv has much higher
mechanical  strength  than  its  predecessor  due  to  the  use  of  higher  compaction
pressures  during tabulating.  DuraSolv tablets are prepared by using conventional
tabletting  equipment  and  have  good  rigidity  (friability  less  than  that  2%).  The
DuraSolv  product  is  thus  produced  in  a  faster  and  more  cost-effective  manner.
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DuraSolv  is  so  durable  that  it  can  be  packaged  in  traditional  blister  packaging,
pouches  or  vials.  One  disadvantage  of  DuraSolv  is  that  the  technology  is  not
compatible  with  larger  doses  of  active  ingredients,  because  the  formulation  is
subjected  to  such  high  pressures  on  compaction.  Unlike  OraSolv,  the  structural
integrity of any taste masking may be compromised with high drug doses. The drug
powder coating in DuraSolv may become fractured during compaction, exposing the
bitter-tasting drug to a patient’s taste buds. Therefore, the DuraSolv technology is
best suited for formulations including relatively small doses of active compound.
Sheaform Technology
This  technology make Sheaform matrix  consisting of  floss  preparation.
Floss  is  produced by subjecting to  a  feedshock  containing a sugar  to  flash heat
processing.
Ceform Technology
In this technology microspheres containing active ingredient are prepared.
Basic requirement of this technology is placing dry powder containing either pure
drug or special  blend of  drug and excipients.  The microspheres  then  mixed and
compressed into previously selected oral dosage form. 
Lyoc (Laboratories L. Lafon, Maisons Alfort , France )
Lyoc  utilizes  a  freeze  drying  process  but  differ  from Zydis  in  that  the
product is frozen on the freeze dryer shelves. To prevent sedimentation during this
process,  these  formulations  require  a  large  proportion  of  undissolved  inert  filler
(mannitol),  to  increase  the  viscosity  of  the  inprocess  suspension.  The  high
proportion  of  filler  reduces  the  potential  porosity  of  the  dried  dosage  form and
results  in  denser  tablets  with  disintegration  rates  that  are  Comparable  with  the
loosely compressed fast melt formulations.
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Pharmaburst technology
Pharmaburst™ is  a  “Quick  Dissolve”  delivery  system patented  by  SPI
Pharma. Pharmaburst is a co-processed excipient system with specific excipients,
which  allows  rapid  disintegration  and  low adhesion  to  punch  facesmouldablilty
saccharides  are  used  to  obtain rapid  melting strong  tablet.  The  active  ingredient
mixes with low mouldablilty saccharides.
Frosta technology
Akina patents this technology. It utilizes the concept of formulating plastic
granules and compressing them at low pressure to produce strong tablets with high
porosity. Plastic granules composed of porous and plastic material, water penetration
enhancer, and binder. The process involves mixing the porous plastic material with
water  penetration  enhancer  followed  by  granulating  with  binder.  The  tablets
obtained have excellent hardness and rapid disintegration time ranging from 15 to 30
sec depending on size of tablet.
Nano technology
For fast dissolving tablets, Elan’s proprietary NanoCrystal technology can
enable formulation and improve compound activity and final product characteristics.
Decreasing particle size increases the surface area,  which leads to an increase in
dissolution  rate.  This  can  be  accomplished  predictably  and  efficiently  using
NanoCrystal technology. NanoCrystal™ Fast dissolving technology provides for:
• Pharmacokinetic  benefits  of  orally  administered  nanoparticles  (<2
microns) in the form of a rapidly disintegrating tablet matrix
• Product differentiation based upon a combination of proprietary and
patent-protected technology elements.
• Cost-effective  manufacturing  processes  that  utilize  conventional,
scalable unit operations.
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Table-3 ODT Patented Technologies and Corresponding Commercial Products 41
Technologies
Company
name
Products on market
DuraSolv®,
OraSolv®
CIMA
Tempra®,  FirsTabs,  Trimainic  ®,  Softchews,
Remeron®,  SolTabs,  Zomig® Rapimelt,  Nulev®,
Alavert®, Parcopa, Niravam, Clarinex Redi Tabs
Flash Dose Biovail Neruofen
Flashtab Ethypharm Nurofen
Kryotab Biotron None
OraQuick KV
Pharmaceutical
None
Quick-Dis Lavipharm Lab Film none
RapitrolTM Shire Lab None
Slow-DisTM
Lavipharm
Lab
Film none
WOWTAB Yamanouchi Benadryl Fastmelt
Advatab Eurand None
Zydis
Cardinal
Health
Maxalt  MLT,  Claritin  Reditabs,  Zyprexa  Zydis,
Zofran ODT
Lyoc Cephalon
Proxalyoc  (piroxicam),  Paralyoc  (paracetamol),
SpasponLyoc (loperamide)
1.7 POSSIBLE  BENEFITS  OF  ORALLY  DISINTEGRATING
DRUGS42,43.
Clinical
 Improved drug absorption
 Faster onset of action
 Minimized first-pass effect
 Improved bioavailability
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Medical 
 No tablet or capsule to swallow or chew.
 Better taste, no water needed.
 Improved safety and efficacy.
 Improved compliance
 The  risk  of  chocking  or  suffocation  during  oral  administration  of
conventional  formulations  due  to  physical  obstruction  is  avoided,
thus providing improved safety.
Technical
 More accurate dosing than liquid products.
 Can use sugars and other excipients that are generally recognized as safe.
 Improved stability because of unit-dose packaging.
 Manufacturing with common process and conventional equipment.
Business
 Unique product differentiation
 Value-added product line extension
 Marketing exclusivity
 Extended patent protection 
 Product differentiation
 Line extension and life cycle management.
 Exclusivity of product promotion
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1.8  TASTE
Taste is  a  sensation, which is  realized when a substance such as  food,
beverages or drug is placed in the oral cavity. This sensation is the result of signal
transduction  from the  receptor  organ  for  taste,  commonly known as  taste  buds.
These taste buds contain very sensitive nerve endings, which produce and transmit
electrical impulses via the seventh, ninth and tenth cranial nerves to those areas of
the brain, which are devoted to the perception of the taste buds.44
Figure 3: Tongue with localized taste buds.45
1.8.1 Anatomy and Physiology of Tongue
Physiologically,  taste  is  a  sensory  response  resulting  from  a  chemical
stimulation of taste buds on the tongue. The sense of taste is conducted to the brain
by a process called taste transduction. This process begins with the interaction of
tastant (i.e., food or medicine) with taste receptor cells in the taste buds. The tastant
binds with G-protein coupled receptors in the cells, triggering the release of a G-
protein  called  gustducin.  Taste  sensation  begins  when  gustducin  activates  the
effector  enzymes  phosphodiesterase  1A  or  phospholipase  C  β-2.  The  effector
enzymes then change the intracellular levels of second messengers such as cyclic
adenosine  monophosphate  (cAMP),  inositol  1,  4,  5  triphosphate  (IP3),  and
idacylglycerol  (DAG).  The  second  messengers  activate  ion  channels,  including
calcium channels inside the cell, and sodium, potassium and calcium channels on the
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extracellular membrane. This ionization depolarizes the cell, causing the release of
neurotransmitters that send a nerve impulse to the brain that carries the signal of
taste.46
In mammal’s taste buds are aggregations of 30-100 individual elongated
“intraepithelial” cells, which are often embedded in specialization of surrounding
epithelium, termed papillae. At the apex of taste bud, microvillus process protrudes
through a small opening, the taste pore, into the oral milieu. At the base of the taste
bud, afferent taste bud, afferent taste nerve invade the bud and ramify extensively,
each fibre typically synapse with multiple receptor cells within the taste bud.
The taste buds are found on three types of papillae on the tongue.
1. A large  number  of  taste  buds  are  on  the  wall  of  the  troughs  that
surround the circumvallated papillae,  which forms ‘V’  line on the
posterior surface of the tongue.
2. Moderate numbers of taste buds are on fungi from papillae over the
flat anterior surface of the tongue.
3. Moderate  numbers  are  on  the  foliate  papillae  located  in  the  folds
along the lateral surface of the tongue.
4. Additional  taste  buds  are  located  on  the  palate  and  few  on  the
tonsillar pillars, the epiglottis and even in the proximal esophagus.
1.8.2 Innervations of Tongue
The receptor cell does not have axons. Transmitter relays information onto
terminals of sensory fibers. These fibers arise from the ganglion cells of the cranial
nerves VII (Facial – branch called the chorda tympani) and IX.
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Figure 4: Papillae and taste buds47
1.8.3 Type of Taste
There  are  five basic  tastes  i.e.,  sour,  salty,  sweet,  bitter, and "umami".
These are called the primary sensations of taste.
a) Sour Taste: Acids cause the sour taste, that is, by the hydrogen ion
concentration,  and  the  intensity  of  this  taste  sensation  is
approximately  proportional  to  the  logarithm  of  the  hydrogen  ion
concentration. That is, the more acidic the food, the stronger the sour
sensation becomes.
b) Salty Taste: Ionized salts elicit the salty taste, mainly by the sodium
ion concentration. The quality of the taste varies somewhat from one
salt  to  another,  because  some  salts  elicit  other  taste  sensations  in
addition  to  saltiness.  The  cations  of  the  salts,  especially  sodium
cations, are mainly responsible for the salty taste, but the anions also
contribute to a lesser extent.
c) Sweet Taste: The sweet taste is not caused by any single class of
chemicals.  Some  of  the  types  of  chemicals  that  cause  this  taste
include sugars, glycols, alcohols, aldehydes, ketones, amides, esters,
some acids, some small proteins, sulfonic acids, halogenated acids,
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and inorganic salts of lead and beryllium. Most of the substances that
cause a sweet taste are specifically organic chemicals. Slight changes
in the chemical structure,  such as addition of a simple radical, can
often change the substance from sweet to bitter.
d) Bitter Taste: The bitter taste, like the sweet taste, is not caused by
any single type  of chemical  agent.  Here again,  the substances that
give  the  bitter  taste  are  almost  entirely  organic  substances.  Two
particular classes of substances are especially likely to cause bitter
taste  sensations:  (i)  long-chain  organic  substances  that  contain
nitrogen, and (ii) alkaloids. The alkaloids include many of the drugs
used in medicines, such as quinine, caffeine, strychnine, and nicotine.
Some substances that at first taste sweet have a bitter aftertaste. This
is true with saccharin, which makes this substance objectionable to
some people. The bitter taste, when it occurs in high intensity, usually
causes the person or animal to reject the food. This is an important
function  of  the  bitter  taste  sensation,  because  many deadly toxins
found in  poisonous plants  are  alkaloids,  and virtually  all  of  these
cause intensely bitter taste, usually followed by rejection of the food.
e) Umami  Taste: Umami is  a  Japanese  word  (meaning  "delicious")
designating a pleasant taste sensation that  is  qualitatively different
from sour, salty, sweet, or bitter. Umami is the dominant taste of food
containing L-glutamate, such as meat extracts and aging cheese, and
some  physiologists  consider  it  to  be  a  separate,  fifth  category  of
primary taste stimuli. A taste receptor for L-glutamate may be related
to one of the glutamate receptors expressed in neuronal synapses of
the brain.  However,  the precise molecular  mechanisms responsible
for umami taste are still unclear.
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1.8.4 Mechanism of Stimulation of Taste
The membrane of the taste cell, like that of most other sensory receptor
cells, is negatively charged on the inside with respect to the outside. Application of a
taste substance to the taste hairs causes partial loss of this negative potential-that is,
the  taste  cell  becomes  depolarized. In  most  instances,  the  decrease  in  potential,
within a wide range, is approximately proportional to the logarithm of concentration
of the stimulating substance. This  change in electrical potential in the taste cell is
called the receptor potential for taste.
The mechanism by which most stimulating substances react with the taste
villi to initiate the receptor potential is by binding of the taste chemical to a protein
receptor molecule that lies on the outer surface of the taste receptor cell near to or
protruding through a  villus  membrane.  This,  in  turn,  opens  ion channels,  which
allows positively charged sodium ions or hydrogen ions to enter and depolarize the
normal negativity of  the cell.  Then the taste  chemical  itself is  gradually washed
away from the taste villus by the saliva, which removes the stimulus.
The type  of receptor  protein in each taste villus determines the type of
taste that will be perceived. For sodium ions and hydrogen ions, which elicit salty
and  sour  taste  sensations,  respectively,  the  receptor  proteins  open  specific  ion
channels in the apical membranes of the taste cells, thereby activating the receptors.
However,  for  the  sweet  and  bitter  taste  sensations,  the  portions  of  the  receptor
protein  molecules  that  protrude  through  the  apical  membranes  activate  second-
messenger transmitter substances inside the taste cells, and these second messengers
cause intracellular chemical changes that elicit the taste signals.
On first application of the taste stimulus, the rate of discharge of the nerve
fibers from taste buds rises to a peak in a small fraction of a second but then adapts
within  the  next  few  seconds  back  to  a  lower,  steady  level  as  long  as  the  taste
stimulus remains. Thus, the taste nerve transmits a strong immediate signal, and a
weaker continuous signal is transmitted as long as the taste bud is exposed to the
taste stimulus.48
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Figure 5: A taste receptor cell49
1.9 TASTE MASKING OF ORAL PHARMACEUTICALS
Taste  masking  is  of  critical  importance  for  active  ingredients  with  an
unpleasant  bitter  taste,  due  to  the  need  for  increased  patient  compliance.  Taste
masking technology involves the development of a system that prevents the active
substance  interacting  with  the  taste  buds,  thereby  eliminating  or  reducing  the
negative sensory response. There are three general taste masking principles, the use
of a physical barrier, chemical or solubility modification, and solid dispersions, each
of them further  subdivided  into several  methods.  Additionally,  unique  platforms
such as orally disintegrating and chewable tablets, applicable for taste masking have
been extensively employed.50
Taste masking of drug may be achieved with preventing the exposure of
drug to the tongue through processing or adding competing taste-masking agents.
Exposure of solubilized drug to the oral cavity can be prevented by encapsulation in
polymer systems or complexation. The approaches are as follows:
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A) Layer/Coat Process
The layering process involves deposition of successive layers of an active
compound onto  the  granules  of  the  inert  starter  seeds  such  as  sugar  spheres  or
microcrystalline  cellulose  beads.  Sugar  spheres  (Non  Pareil)  or  microcrystalline
spheres (Celpheres) can be used as initial substrate in the preparation of beads by the
layering process. In the layering process, the bitter drug is dissolved or dispersed in
an aqueous or non-aqueous solvent, depending on its solubility characteristics and
ease of processing. Binder is added to the solution to form liquid bridges between
the  primary  particles.  Most  commonly  used  binders  are  gelatin,  povidone,
carboxymethyl  cellulose,  hydroxypropyl  methylcellulose (HPMC),  hydroxypropyl
cellulose (HPC), and maltodextrin.51 In solution form, the drug is completely soluble
in the solvent, while in dispersed form, the drug is either micronized before adding
into the solvent or the solvent containing dispersed drug is subjected to wet milling
using a high-shear mixer to micronize in solution. It  is desirable that the ratio of
particle  size  of  the  drug  to  the  size of  the beads  is  about  1:10.  In  the layering
process, drug layering up to 100–150% in weight is achievable, beyond which drug
layering  may cause excessive grittiness  because  of  increased  particle  size of  the
granules  when  incorporated  into  a  dosage  form.  A  potential  disadvantage
encountered during drug layering process is the possibility of drug recrystallizing
into different polymorphs upon completion of the process.
After the drug is layered over an inert starting material, it is then coated
with  a  polymer  that  retards  dissolution  in  the  oral  cavity.  Two  mechanisms  to
prevent  dissolution  are  predominantly  used,  either  a  polymer  that  slows  down
dissolution across all pHs or a polymer that does not dissolve in the pH of the saliva
but dissolves rapidly in the gastric fluid of the stomach. The various polymers used
for  taste-masking  purpose  are  Eudragit  E  100,  ethylcellulose,  HPMC,  HPC
polyvinyl alcohol, and polyvinyl acetate. The polymer is dissolved in an aqueous or
non-aqueous solvent depending on its solubility characteristic and antitack agents
such as talc, magnesium stearate, and cab-o-sil are added to improve processing and
prevent  agglomeration.  Sometimes  taste  masking  is  possible  by  combining
layer/coat  in  a  single  process,  i.e.,  incorporating the  drug  in  solution/suspension
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form containing a polymer that serves both as a binder and as a taste-masking agent
and then depositing the drug onto beads.
       
(a)                            (b)                      (c)
Figure 6: Types of coating.  (a) Top spray batch fluid coating. (b) Bottom
spray  batch  fluid  coating.  (c)  Tangential  spray  batch  fluid
coating.52
B) Granulation
Taste masking by granulation is achieved by decreasing the surface area of
the drug by increasing its particle size. The additional benefit obtained is ease of
processing for tablet compression as the majority of drugs have a low bulk density.
Additionally,  polymers  that  serve  as  binders  and  taste-masking  agents  may  be
incorporated,  which reduce the perception of taste.  Granulation may be achieved
with or without the use of a solvent. Dry granulation involves the use of forming
compacts/slugs  that are milled for blending. Wet granulation can be achieved by
using the fluid bed process or high-shear granulation. In the fluid bed process, the
drug is suspended in the bed with air, and a binder is sprayed from the top. The
granules formed are porous and not amenable to further processing like coating. In
high-shear  granulation,  the granule  formation occurs  by spraying  a liquid binder
onto drug/mixture  of  drugs  with  excipients  that  are  being  agitated  by combined
action of an impeller and chopper. The granules obtained are dense and may be used
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directly or  coated further  in a  fluid bed. This approach is suitable for  high-dose
drugs (>50 mg) with unpleasant taste.
C) Spray Drying
For  taste-masking application,  the drug is  either  dissolved  or  dispersed
along with bulking agent (polymer) and, occasionally, a binding agent is also added
if required, in a suitable solvent. Spray drying consists of four stages: atomization of
feed  into  a  spray,  spray–air  contact  (mixing  and  flow),  drying  of  spray
(moisture/volatiles evaporation), and separation of dried product from the air.53 The
solvent  used for  spray drying  process  may be  aqueous  or  non-aqueous.  Product
obtained  upon  spray  drying  yields  high  porosity  granules  or  beads  containing
encapsulated drug. Some unintended effects include formation of solid dispersions
of  the  drug  owing  to  recrystallization  and  thermal  degradation  for  temperature-
sensitive drugs.
D) Complexation
Taste  masking  by  inclusion  complexation  is  possible  by  physically
entrapping the drug in cone-shaped structures called cyclodextrins.54  Cyclodextrins
are bucket shaped oligosaccharides produced from starch. Owing to their peculiar
structure  and  shape,  they  possess  the  ability  to  entrap  guest  molecules  in  their
internal cavity. Drug inclusion complexes can be formed by a variety of techniques
that depend on the property of the drug, the equilibrium kinetics, other formulation
ingredients, processes, and the final dosage form desired. In all these processes, a
small amount of water is required to achieve thermodynamic equilibrium. The initial
equilibrium to form the complex is very rapid; the final equilibrium takes a longer
time. The drug, once inside the cyclodextrin cavity, makes conformational changes
to itself so as to attach itself to the complex and to take maximum advantage of the
weak vander waals forces. Complexation is also possible through the use of ion-
exchange resins. Both anionic and cationic types are available.55  The preparation of
the taste-masked complex involves suspending the resin in a solvent in which the
drug is dissolved. For liquid preparations, the drug–resin complex can be used as is.
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For solid dosage forms, the complex may be processed by filtration or direct drying.
Drug loading up to 50% is possible with this process. Some commercially available
ion-exchange resins that may be used for taste masking are based on methacrylic
acid and divinyl benzene and styrene divinyl benzene polymer.56 
E) Psychological Modulation of Bitterness
Taste masking with addition of competing agents involves modulating the
psychological  perception  of  bitterness.  To  understand  this  better,  the  theory  of
perception of taste is in order. The biochemical and physiological basis of bitterness
has been summarized recently6, 57. There are two theories. One theory contends that
receptors  for  common taste  stimuli  such  as  salt,  bitter,  and sweet  are present  in
specific locations of the tongue. The second theory contends that taste buds respond
to all stimuli to a different extent. Regardless of the mechanism, taste masking is
achieved by the addition of specific inhibitors to suppress the stimuli. This approach
is likely to involve the use of an inhibitor specific to the taste masking of the drug in
question. In  general,  there is  no specific  universal  inhibitor available,  which will
mask all the taste stimuli.
F) Coacervation
Coacervation leads to formation of a microencapsulated form of drug. The
process primarily consists of formation of three immiscible phases, formation of the
coat, and deposition of the coat. The formation of the three immiscible phases is
accomplished  by  dispersing  the  core  particles  in  a  polymer  solution.  A  phase
separation is  then induced by changing the temperature  of  the polymer  solution,
addition of a salt and nonsolvent, or by inducing a polymer–polymer  interaction.
This leads to deposition of the polymer coat on the core material under constant
stirring. The core particles coated by the polymer are then separated from the liquid
phase by thermal, cross-linking, or desolvation techniques leading to rigidization of
the coat.
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G) Extrusion Spheronization
The  process  begins  with  the  blending  of  dry  powders  followed  by
granulation. The granulation is different from conventional granulation as the end
point is determined by the consistency of the paste suitable for passing through an
extruder. After passing through the extruder, the granulate is in the form of rods.
The rods can then be passed through a spheronizer to form pellets, which are then
dried. An advantage touted for extrusion spheronization is the formation of more
spherical pellets compared to wet granulation.57 Hot-melt extrusion involves passing
a molten solid dispersion of the drug through a extruder to obtain pellets. The hot-
melt extrudate consists of drug dispersed in a molten hydrophilic matrix, which is
then passed through an orifice in the extruder. The extruder paste can then be passed
through a spheronizer to obtain pellets that are subsequently cooled. This process is
primarily used for increasing the solubility of poorly soluble drugs as it leads to
formation  of  amorphous  form  of  the  drug;  however,  the  appropriate  choice  of
polymers could lend itself to taste masking. The advantage touted for this is better
control of particle size of the pellets and absence of the use of solvents.
Figure 7: Extruder and spheronizer58
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            Extruded product              Breaking up                     Spheronizing                  
Figure 8: Process of pellet formation58
1.10 SUPERDISINTEGRANTS AND ODT59
Superdisintegrant  plays  the major  role in  oral  disintegrating tablet.  The
disintegration  efficiency  is  based  on  the  force-equivalent  concept  (the  combined
measurement  of  swelling  force  development  and  amount  of  water  absorption).
Superdisintegrants  are  generally  used  at  a  low  level  in  the  solid  dosage  form,
typically 1 – 10 % by weight relative to the total weight of the dosage unit.
 Common disintegrants used are Croscarmellose sodium (Vivasol, Ac-Di-
Sol),  Crospovidone  (Polyplasdone),  Carmellose  (NS-300),  Carmellose  calcium
(ECG-505), Sodium starch glycolate (SSG) etc. Recently few ion exchange resins
(e.g. Indion 414) are found to have superdisintegrant property and are widely used in
pharmaceutical industry.
1.10.1 Method of Addition of Disintegrants
Disintegrants  are essentially added to  tablet  granulation for  causing the
compressed  tablet  to  break  or  disintegrate  when placed  in  aqueous environment.
There are three methods of incorporating disintegrating agents into the tablet: 
I. Internal Addition (Intragranular)
II. External Addition (Extragranular) 
III. Partly Internal and External 
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In  external  addition  method,  the  disintegrant  is  added  to  the  sized
granulation  with  mixing  prior  to  compression.  In  Internal  addition  method,  the
disintegrant is mixed with other powders before wetting the powder mixtures with
the  granulating  fluid.  Thus  the  disintegrant  is  incorporated  within  the  granules.
When these methods are used, part of disintegrant can be added internally and part
externally.  This  provides  immediate  disruption  of  the  tablet  into  previously
compressed  granules  while the disintegrating agent  within the granules  produces
further erosion of the granules to the original powder particles. 
1.10.2 Mechanism of Tablet Disintegrants59
The  tablets  were  broken  into  small  pieces  and  then  produces  a
homogeneous suspension which is based on the following mechanisms: 
Capillary action/ Water wicking
Disintegration by capillary action is always the first step. When we put the
tablet  into  suitable  aqueous  medium,  the  medium penetrates  into  the  tablet  and
replaces the air adsorbed on the particles, which weakens the intermolecular bond
and  breaks  the  tablet  into  fine  particles.  Water  uptake  by  tablet  depends  upon
hydrophilicity of the drug/excipient  and on tableting conditions.  The ability of a
disintegrant  to  draw  water  into  the  porous  network  of  a  tablet  is  essential  for
effective  disintegration.  Wicking  is  not  necessarily  accompanied  by  a  volume
increase.
By Swelling
Perhaps the most widely accepted general mechanism of action for tablet
disintegration is swelling. It is worthwhile to note that if the packing fraction is very
high, fluid is unable to penetrate into the tablet and disintegration again slows down.
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Air expansion /Heat of wetting 
When  disintegrants  with  exothermic  properties  gets  wetted,  localized
stress is generated due to capillary air expansion, which helps in disintegration of
tablet. 
Due to disintegrating particle/particle repulsive forces
Another mechanism of disintegration attempts to explain the swelling of
tablet  made  with  ‘non-swellable’  disintegrants.  Non-swelling  particles  cause
disintegration  of  tablets.  The  electric  repulsive  forces  between  particles  are  the
mechanism of disintegration and water  is  required for  it.  Researchers  found that
repulsion is secondary to wicking.
Due to deformation
During tablet compression, disintegrated particles get deformed and these
deformed particles get into their normal structure when they come in contact with
aqueous media or water. This increase in size of the deformed particles produces a
breakup of the tablet. This may be a mechanism of starch and has only recently
begun to be studied.
Due to release of gases
Carbon dioxide is  released  within tablets  on wetting due to  interaction
between  bicarbonate  and  carbonate  with  citric  acid  or  tartaric  acid.  The  tablet
disintegrates due to generation of pressure within the tablet. The effervescent blend
is either added immediately prior to compression or can be added in to two separate
fraction of formulation.
By Enzymatic reaction
Here, enzymes presents in the body act as disintegrants. These enzymes
destroy the binding action of binder and helps in disintegration.    
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Mechanism of Action of Superdisintegrant
Figure9:  Mechanism of action of Superdisintegrant
Table-4 Superdisintegrants Employed in ODTs.60,61.
Superdisintegrant Nature Properties Mechanism
Crosspovidone Crosslinked  homo
polymer of N-vinyl-
2-pyrrolidone
Particle  size  -  100ìm.
Insoluble  in  water.
Gives  smoother  mouth
feel.
Both  swelling
and wicking
Cross carmellose 
sodium
Cross-linked form of
sodium CMC
Particle  size  -  200ìm.
Insoluble in water. Swelling
Sodium starch 
glycolate
Crosslinked  low
substituted  carboxy
methyl  ether  of
poly-glucopyranose
Particle size - 140mesh.
Insoluble  in  organic
solvents,  disperses  in
cold water and settles in
the  form  of  a  highly
saturated layer. 
Water  uptake
followed  by
rapid  and
enormous
swelling.
Acrylic acid 
derivatives
Poly  (acrylic  acid)
super  porous
hydrogel
Particle  size  -  106ìm.
DT – 15 + 2 s Wicking action
Effervescent
mixture
Citric  acid,  tartaric
acid,  sodium
bicarbonate. 
Crystalline nature Effervescence
Sodium alginate Sodium  salt  of
alginic acid
Slowly soluble in water,
hygroscopic in nature
Swelling
L-HPC
Low hydroxy propyl
cellulose
Particle  size  -  106ìm.
DT – 90 s
Both  swelling
and wicking
Table-5 ODT Products Available in International Market.62
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Brand name Active ingredient Company
Alavert Loratadine Wyeth Consumer Healthcare
Cibalginadue FAST Ibuprofen Novartis Consumer Health
Hyoscyamine Sulfate ODT Hyoscyamine sulfate ETHEX Corporation
NuLev Hyoscyamine sulfate Schwarz Pharma
Benadryl Fastmelt Diphenhydramine Pfizer
Nurofen flash tab Ibuprofen Boots Healthcare
Zomig ZMT & Rapimelt Zolmitriptan Astra Zeneca
Excedrin Quick Tabs Acetaminophen Bristol-Myers Squibb
Claritin RediTabs Loratadine Sching Corporation
Remeron SolTab Mirtazepine Organon Inc
Feldene Melt Piroxicam Pfizer
Propulsid Quicksolv Cisapride monohydrate Janssen
Imodium Instant melts Loperamide HCL Janssen
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REVIEW OF LITERATURE
               
R. Mandrioli et al, 66 carried out Two different analytical methods for the
quality control of fluoxetine in commercial formulations have been developed and
compared: a spectrofluorimetric method and a capillary zone electrophoretic (CZE)
method. The fluorescence emission values were measured at =293 nm when exciting
at =230 nm. The CZE method used an uncoated fused-silica capillary and pH 2.5
phosphate buffer as the background electrolyte. The extraction of fluoxetine from
the  capsules  consisted  of  a  simple  one-step  dissolution  with  methanol/water,
filtration and dilution. Both methods gave satisfactory results in terms of precision;
the best results were obtained for the electrophoretic method, with RSD% values
always lower than 2.0%. The accuracy was assessed by means of recovery studies,
which gave very good results, between 97.5 and 102.6%. Furthermore, both methods
also have the advantage of being very rapid.
Bernard  A.Olsen  et  al,  67 carried  out  Chromatographic  methods  using
chiral  stationary  phases  have  been  developed  for  the  separation  of  fluoxetine
hydrochloride  enantiomers.  Ovomucoid  and  tris(3,5-dimethylphenyl  carbamate)
cellulose  stationary phases  were  used  in  the  reversed-  and  normal-phase  modes,
respectively.  Acceptable  isomer  separation  was  achieved  at  pH  3.5  with  the
ovomucoid phase, but peak shapes were broad and the separation was quite sensitive
to the acetonitrile concentration in the mobile phase. Isopropyl alcohol and methyl-
tert-butyl ether mobile phase modifiers each provided complete resolution using the
derivatized  cellulose  column.  Better  separation  robustness  was  obtained  with  a
column temperature of 1°C using the isopropyl alcohol modifier. The methyl-tert-
butyl  ether  system  was  robust  at  room  temperature.  Differences  in  relative
enantiomer amount of as little as 2% could be determined. The chromatographic
conditions provided a much more discriminating test compared to an optical rotation
method  proposed  for  pharmacopeial  use  which  had  difficulty  distinguishing
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individual enantiomers. The chiral chromatographic conditions were also applied to
capsule  formulations  to  demonstrate  the  presence  of  racemic  fluoxetine
hydrochloride
Rubesh kumar et al, 68 carried out an analytical method development and
validation  of  Fluoxetine  HCl  (FLU)  and  Olanzapine(OLZ)  in  bulk  drug  and
pharmaceutical  dosage  form. The developed  method is  based upon simultaneous
equations (Vierodt’s) method by using UV/Visible spectroscopy. Both drugs come
in the categories of anti- depressant and antipsychotic agent. The developed method
can be used for the simultaneous estimation of FLU and OLZ in pharmaceutical
dosage form without separating from each other or from the excipients. Primarily
the  ë  max  of  Fluoxetine  Hydrochloride  (FLU)  and  Olanzapine  (OLZ)  was
determined as 226 and 258 nm respectively. The suggested method is validated by
using ICH validation parameters like accuracy, precession, linearity and LOD and
LOQ respectively. This procedure was applied successfully for the analysis of FLU
and OLZ in bulk drug and Pharmaceutical preparations. 
 Rajani  Giridhar  et  al,  69 developed  Two  new  rapid,  sensitive  and
economical  spectrophotometric  methods  are  described  for  the  determination  of
fluoxetine hydrochloride in bulk and in pharmaceutical formulations. Both methods
are based on the formation of a yellow ion-pair complex due to the action of methyl
orange  (MO) and  thymol  blue  (TM)  on  fluoxetine  in  acidic  and  basic  medium,
respectively.  Under optimised conditions they show a absorption maxima at some
particular nm with a particular molar absorptivities and Sandell’s Sensitivities at a
thousandth part of absorbance unit for MO and TB, respectively. The color is stable
for  5  min  after  extraction.  In  both  cases  Beer’s  Law  is  obeyed  at  smaller
concentrations with MO and TB. The proposal method was successfully extended to
pharmaceutical preparations—capsules. The results obtained by both the agreement
and  E.P.  (3rd  edition)  were  in  good  agreement  and  statistical  comparison  by
Student’s  t-test  and variance  ratio  F-test  showed no significant  difference  in  the
three methods.
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M.A.Raggi  et  al,  70 carried  out  some  analytical  methods  (two
spectrophotometric and two chromatographic procedures) for the determination of
fluoxetine in Prozac® capsules are described. All of them are applied to the samples
after extracting the drug with a methanol–water mixture. The direct and derivative
spectrophotometric  methods are simple and reliable;  the derivative method gives
better recovery and lessens interference. Both methods show linearity in the 5–30
mg  ml_1  range  of  the  fluoxetine  concentration  range.  Both  HPLC  methods
(spectrophotometric and spectrofluorimetric detection) use a tetramethylammonium
perchlorate buffer–acetonitrile mixture as the mobile phase and a C8 reversed phase
column. The UV detection is performed at 226 nm, while the fluorimetric detection
is  performed by exciting at  230 nm and revealing the emission at  290 nm. The
HPLC  method  with  UV  detection  is  more  precise,  but  the  procedure  with
fluorimetric detection is more sensitive.
Mohamad A.El-dawy at el, 71  developed a simple, accurate and sensitive
high pressure liquid chromatographic technique is described for the determination of
fluoxetine  in  the  capsule  dosage  form,  human  plasma  and  in  biological  fluid.
Analysis is performed with a reversed phase-C18 column with ultraviolet detection
at  228 nm. The isocratic  mobile phase (1.5  ml/min.)  consists  of acetonitrile  and
triethylamine buffer (48/52, V/V). A linear calibration model (correlation coefficient
0.99863) was developed using pyridoxine as internal standard. The retention times
were 2.10 and 3.20 min for pyridoxine and fluoxetine, respectively. The method was
applied for  the  quantitation of  fluoxetine  in  spiked  human plasma samples.  The
detection limit is 5 mg/l and the absorbance varies with fluoxetine concentrations in
the  range  (10/300)  mg/l.  The  mean  %  recovery9/S.D.  was  found  to  be
97.99%9/2.39.  The proposed  method was  applied  successfully  for  monitoring of
fluoxetine in human plasma after single dose administration of one prozac
CH.Hareesha  et  al, 72 worked  on  Escitalopram  Oxalate  used  as
Antidepressant.  The  present  investigation  deals  with  the  formulation  of  oral
disintegrating tablets of baclofen that disintegrate in the oral  cavity upon contact
with saliva and there by improve therapeutic efficacy. The odts were prepared by
direct compression technique. It  is observed in the formulations   that comparing
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micro crystalline cellulose with mannitol as a filling agent, mannitol shows better
release of api
Kalpesh gur et al, 73developed the fast disintegrating tablets of aceclofenac
were prepared by subliming method with a view to enhance patient compliance. In
this paper, two super-disintegrants, viz., crospovidone and sodium starch glycolate
were used in different ratio (2-8 % w/w) with camphor (30 % w/w) as subliming
agent. The prepared batches of tablets were evaluated for thickness, weigh variation,
hardness, friability, drug content uniformity, wetting time, water absorption ratio, in-
vitro  disintegration  time and  in-vitro  drug  release.  Based  on  disintegration  time
(approximately  21  second),  three  formulations  were  tested  for  the  in-vitro  drug
release  pattern  (in  ph  7.4  phosphate  buffer).  Among  the  three  promising
formulations,  the  formulation  prepared  by  using  8%  w/w  of  crospovidone  and
emerged  as  the  overall  best  formulation  based  on  the  in-vitro  drug  release
characteristics. 
Uma vasi reddy et al, 74  compared the effect of superdisintegrants on the
mouth dissolving property of salbutamol sulphate tablets. Orodispersible tablets of
salbutamol  sulphate  of  prepared  using  sodium starch  glycollate,  crosscarmellose
sodium  as  superdisintegrants.  The  results  revealed  that  the  tablets  containing
subliming agent had a good dissolution profile. The optimized formulation showed
good release profile with maximum drug being released at all time intervals. This
work  helped  us  in  understanding  the  effect  of  formulation  processing  variables
especially  the  Superdisintegrants  on  the  drug  release  profile.  The  present  study
demonstrated  potentials  for  rapid  absorption  improved  bioavailability  effective
therapy and patient compliance.
Prameela rani. A et al, 75 metformin hcl (met.hcl) is an orally administered
hypoglycemic agent,  used in the management  of  non‐insulin‐dependent  (type‐2 )
diabetes.  As  precision  of  dosing  and  patient’s  compliance  become  important
prerequisite  for  a  long  term  antidiabetic  treatment,  there  is  a  need  to  develop
formulation  for  this  drug  which  overcomes  problems  such  as  difficulty  in
swallowing,  inconvenience  in  administration  while  travelling  and  patient’s
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acceptability. Hence in the present study an attempt has  een made to prepare fast
disintegrating tablets of met.hcl in the oral cavity with enhanced dissolution rate.
The  tablets  were  prepared  with  isphagula  husk,  natural  superdisintegrant  and
crosspovidone,  synthetic  superdisintegrant.  The  pure  drug and formulation blend
was examined for angle of repose, bulk density,  tapped density,  commpressibility
index and haussner’s ratio. The tablets were evaluated for hardness, tensile strength,
drug content, friability and were found satisfactory. The disintegration time in the
oral cavity was also tested and was found to be around 10sec. Based on dissolution
rate  the  disintegrants  can  be  rated  as  isphagula  husk  >  crosspovidone.  Hence
ishagula husk was recommended as suitable disintegrant for the preparation of direct
compression melt‐in‐mouth tablets of met.hcl. All the dissolution parameters were
calculated and compared with market tablet. A 3.78 fold increase in the dissolution
rate was observed with f4 formulation when compared to market tablet(glucophage).
It was concluded that the rapidly disintegrating tablets with proper hardness, rapid
disintegration in the oral cavity with enhanced dissolution rate can be made using
Superdisintegrants.
Basani get al, 76 baclofen is a muscle relaxant and anti spastic. The present
investigation deals with the formulation of oral disintegrating tablets of baclofen that
disintegrate  in  the  oral  cavity  upon  contact  with  saliva  and  there  by  improve
therapeutic efficacy. The odts were prepared by direct compression technique. The
optimized formulation was also prepared by effervescent method. The influence of
superdisintegrants,  Crospovidone,  croscaremellose  sodium  and  sodium  starch
glycolate at three levels on disintegration time, wetting time and water absorption
ration  were  studied.  Tablets  were  evaluated  for  weight  and  thickness  variation,
disintegration  time,  drug  content,  in  vitro  dissolution,  wetting  time  and  water
absorption ratio. The in vitro disintegration time of the best odts was found to be 14
sec  and  28sec  by  direct  compression  and  by  effervescent  method,  respectively.
Tablets  containing  crospovidone  exhibit  quick  disintegration  time  than  tablets
containing  croscaremellose  sodium,  sodium  starch  glycolate  and  effervescent
mixture. Good correlation was observed between water absorption ratio and dt. The
directly  compressible  rapidly  disintegrating  tablets  of  baclofen  with  shorter
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disintegration time, acceptable taste and sufficient hardness could be prepared using
crospovidone and other excipients at optimum concentration.
Jyotsana madan et al, 77 the objective of this work was to prepare and
evaluate fast dissolving tablets of the nutraceutical, freeze dried aloevera gel. Fast
dissolving tablets of the nutraceutical, freeze-dried aloevera gel, were prepared by
dry  granulation  method.  The  tablets  were  evaluated  for  crushing  strength,
disintegration time, wetting time, friability, drug content and drug release. A 32 full
factorial design was applied to investigate the combined effect of two formulation
variables  -  amounts  of  microcrystalline  cellulose  and  mannitol.  The  results  of
multiple regression analysis revealed that in order to obtain a fast dissolving tablet
of the aloe vera gel, an optimum concentration of mannitol and a higher content of
microcrystalline cellulose should be used. A response surface plot was also provided
to graphically represent the effect of the independent variables on the disintegration
time and wetting time. The validity of the generated mathematical model was tested
by  preparing  a  check  point  batch.  This  investigation  has  demonstrated  that
satisfactory fast dissolving aloe vera gel tablets can be formulated. It also showed
the  potential  of  experimental  design  in  understanding  the  effect  of  formulation
variables on the quality of fast dissolving tablets.
Jashanjit  singh  et  al,78 purpose:  the  objective  of  this  study  was  to
formulate  and  optimize  an  orodispersible  formulation  of  meloxicam  using  a  2
factorial design for enhanced bioavailability.the tablets were made by non-aqueous
wet granulation using crospovidone and mannitol. A 2 factorial design was used to
investigate the amount of crospovidone and taste masking, soothening hydrophilic
agent  (mannitol),  as  independent  variables,  and disintegration  time as  dependent
response.  Formulated  orodispersible  tablets  were  evaluated  for  weight  variation,
friability, disintegration time, drug content, wetting time, water absorption ratio and
in vitro drug release. The results show that the presence of a superdisintegrant and
mannitol is desirable for orodispersion. All the formulations satisfied the limits of
orodispersion with a dispersion time of less than 60 sec. For example, formulation f4
showed a disintegration time of 32.1 sec, crushing strength of 4.93 kg/cm2, drug
content of 98.5% and fast drug release rate of 99.5% within 30 min, as compared
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with  the  conventional  tablet  (49.5%)  .  It  is  feasible  to  formulate  orodispersible
tablets of meloxican with acceptable disintegration time, rapid drug release and good
hardness, which could be amenable to replication on an industrial scale.
furtado et al, 79 showed a purpose of the present research was to the effect
of camphor as a subliming agent on the mouth dissolving property of famotidine
tablets. Method: orodispersible tablets of famotidine were prepared using camphor
as  subliming  agent  and  sodium  starch  glycollate  together  with  crosscarmellose
sodium as superdisintegrants. The formulations were evaluated for weight variation,
hardness,  friability,  drug  content,  wetting  time,  in  vitro  and  in-vivo  dispersion,
mouth feel and in vitro dissolution. Result: all the formulations showed low weight
variation with dispersion time less than 30 seconds and rapid in vitro dissolution.
The  results  revealed  that  the  tablets  containing  subliming  agent  had  a  good
dissolution  profile.  The  drug  content  of  all  the  formulations  was  within  the
acceptable limits of the USP xxvii. The optimized formulation showed good release
profile with maximum drug being released at all  time intervals.  Conclusion: this
work  helped  in  understanding  the  effect  of  formulation  processing  variables
especially  the  subliming  agent  on  the  drug  release  profile.  The  present  study
demonstrated  potentials  for  rapid  absorption,  improved  bioavailability,  effective
therapy and patient compliance.
Anand et al,80 prepared taste-masked orally disintegrating tablets (odts) of
prednisolone (pdl) by incorporation of microspheres in the tablets for use in specifi c
populations  viz.  Pediatrics,  geriatrics  and  patients  experiencing  diffi  culty  in
swallowing.  Methods:  microsphere  containing  pdl  were  prepared  by  the  solvent
evaporation  method using acetone  as  solvent  for  ph-sensitive  polymer  and  light
liquid  paraffi  n  as  the  encapsulating  medium.  Prepared  microspheres  were
characterized  with  regard  to  the  yield,  drug  content,  particle  size  and  size
distribution, surface features, in vitro drug release and taste. Tablets, prepared by
direct compression containing microspheres, were evaluated with regard to crushing
strength,  friability,  disintegration time, drug content and in vitro drug release and
taste. Results: the results obtained showed that the average size of microspheres is
infl uenced greatly by the speed of stirring. Microspheres prepared by the solvent
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evaporation method in acetone were of a regular spherical shape with satisfactory
results in terms of the size and size distribution. The comparison of the dissolution
profi  les  of  microspheres  in  different  media  shows  that  microspheres  produce  a
retarding  effect  in  ph  6.8  buffer.  Taste  evaluation  studies  confirmed  that
microspheres of pdl having a drug to polymer ratio of 1: 10 are tasteless and these
were further used for formulation into odts. Compression of microspheres resulted in
breaking of a fraction of the microspheres but this didnot adversely affect the taste.
Conclusion:  effective  taste-masking was achieved  for  pdl using the technique  of
Microencapsulation  and  odts  of  acceptable  characteristics  were  obtained  by
disintegrant addition and direct compression.
Venkata ramana reddy S et al,81 develop oral disintegrating tablets (odt)
of low bitter hypertensive drugs like amlodipine besylate using tastem enhancers as
a taste  asking agents.  Odt of amlodipine besylate were prepared using different
superdisintegrants by direct compression method. Mannitol was used as a diluent
and sodium lauryl sulphate was used as a wetting (surfactant) agent. Aspartame and
acesulfame potassium were used for unpleasant taste masked from the amlodipine
besylate by cosifting and serial of blending with other excipients. The mixed final
blend was then compressed into tablets. The formulations were evaluated for weight
variation,  hardness,  friability,  wetting  time,  disintegrating  time,  dissolution,  taste
valuation study and in  vitro  dissolution.  All  the formulation showed low weight
variation with different disintegration time and rapid in vitro dissolution. The results
revealed that the tablets containing taste enhancers had a good palatability for the
patients. The optimized formulation showed good taste masking, less disintegration
time (<30seconds) and release profile with maximum drug being released at all time
intervals. The present study demonstrated potentials for rapid disintegration in oral
cavity without water, improved taste masking and patient compliance.
Anantha lakshmi pallikonda et al, 82 formulate and evaluate domperidone
mdt’s. It acts as an ant emetic used in the treatment of motion sickness. Different
batches  of  tablets  were  prepared  using  higher  and  lower  concentrations  of
superdisintegrants  like croscarmellose  sodium, crospovidone  (c.p),  sodium starch
glycolate (ssg), while mcc was used as diluents. Tablets were prepared by slugging
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method.  Different  evaluations  tests  like  hardness,  friability,  wetting  and
disintegration times, % drug release were performed. Tablets containing along with
crospovidone were disintegrate rapidly below 20sec and % drug release is 99% at
4th minute. Increased consumer satisfaction.
Mahaveer  pr.  Khinchi  et  al,  83 Superdisintegrants  (such  as  ac-di-sol,
crospovidone, sodium starch glycolate), diluents (dibasic calcium phosphate) along
with sweetening  agent  (aspartame)  were  used  in  the  formulation  of  tablets.  The
tablets  were  evaluated  for  hardness,  friability,  water  absorption  ratio,  in-vitro
disintegration time (dt), in-vitro disintegration time in oral cavity and in vitro drug
release. Using the same excipients, the tablets were prepared by direct compression
and were evaluated in the similar way. Maximum drug release and minimum dt were
observed with crospovidone excipient prepared by direct compression.
Dr.  Raghavendra  rao  n.  et  al,  84 carried  out  the  study  on  novel  
co-processed  Superdisintegrants  were  developed  by  solvent  evaporation  method
using crospovidone and sodium starch glycolate in different ratios (1:1, 1:2 and 1:3)
for use in the fast  dissolving tablet  formulations.  The developed excipients were
evaluated for angle of repose, carr’s index and hausner’s ratio in comparison with
physical  mixture  of  superdisintegrants.  Fast  dissolving tablets  of felodipine were
prepared  using  the  above  co-processed  superdisintegrants  and  evaluated  for  
pre-compression  and  postcompression  parameters.  Effect  of  co-processed
superdisintegrants (such as crospovidone, and sodium starch glycolate) on wetting
time,  disintegrating  time,  drug  content,  in-vitro  release,  and  stability  parameters
have been  studied.  From this  study,  it  can be  concluded that  dissolution rate  of
felodipine could be enhanced by tablets containing co-processed superdisintegrant.
Suhas m. Kakade et al, 85 Orally disintegrating tablets prepared by direct
compression and using Superdisintegrants like crospovidone, croscarmellose sodium
and  sodium  starch  glycolate  designate,  designated  as  three  different  groups  of
formulation  (  a,  b  and  c)  respectively  were  prepared  and  evaluated  for  the
precompression parameters such as bulk density,  compressibility,  angle of repose
etc. The prepared batches of tablets were evaluated for hardness, weight variation,
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friability, drug content, disintegration time and in-vitro dissolution profile and found
satisfactory. Among the three groups, group (c) containing crospovidone emerged as
the  best  formulation  and  showed  maximum  dissolution  rate  with  98.49%  drug
release in 15 min. All three groups of formulations released the drug at faster rates
than that of marketed conventional tablets of sertraline.
Deshpande kiran bhaskar et al, 86 carrriedout the  study was aimed, which
can  disintegrate  or  dissolve  rapidly  once  placed  in  the  oral  cavity.  Propranolol
hydrochloride  is  a  antihypertensive  drug,  which  undergoes  extensive  hepatic
degradation (96%), which have poor oral bioavailability (26%) for overcoming this
problem  orodispersible  tablets  of  propranolol  hydrochloride  can  be  formulated
which  avoids  extensive  first  pass  metabolism  and  improvement  in  dissolution
efficacy,  disintegration time which results  in improvement in bioavailability.  The
advantage of this formulation is such that in case of hypertension attack patient can
take the drug without the usage of water. Therefore the main objective of the present
work is to develop orodispersible tablets of propranolol hydrochloride to improve
bioavailability, disintegration time, dissolution efficacy and patient compliance.
Tejash serasiya et al, 87 orodispersible tablets of pheniramine maleate were
prepared  by  direct  compression  method  using  various  superdisintegrants  like
crospovidone,  croscarmellose  sodium,  sodium  starch  glycolate,  low  substituted
hydroxypropyl cellulose, pregelatinized starch. The prepared tablets were evaluated
for uniformity of weight,  hardness,  friability,  wetting time, in-vitro disintegration
time, in-vitro  dispersion time and drug release study. All the formulation exhibited
hardness between 3.3 – 3.6 kg/cm2. The tablets were disintegrating in–vitro within
20  to  51  sec.  Dissolution  studies  revealed  that  formulations  containing  10%
crospovidone and formulation containing 10% croscarmellose sodium showed 100%
of drug release, at the end of six min. The concentration of superdisintegrants had an
effect  on disintegration  time and  in-vitro  drug dissolution whereas  hardness  and
friability  of  resulting  tablets  were  found  to  be  independent  of  disintegrant
concentration.  The  two  formulations,  one  containing  10%  of  crospovidone  and
second containing 10% croscarmellose sodium were found to give the best results.
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Pankaj p. Amrutkar et al,88 Carried out the work on  lamotrigine used in
the treatment of depression and bipolar disorder. But it is a bitter drug and slightly
soluble in water. Thus, in the work under taken, an attempt was made to mask the
taste  and  to  formulate  into  a  chewable  dispersible  tablet  by  complexation  with
precirol ato-05, which also acts as taste masking agent. Since, these tablets can be
swallowed in the form of dispersion; it is suitable dosage form for paediatric and
geriatric patients. Drug-precirol ato-05 was prepared in drug to precirol ato-05 ratio
of 1:2, 1:1.5, 1:1, 1:0.5. The prepared tablets were evaluated for general appearance,
content  uniformity,  hardness,  friability,  taste  evaluation,  mouth  feel,  in  vitro
disintegration  time,  and  in vitro  dissolution studies.  Tablets  with  precirol  ato-05
have shown good disintegrating features, also, the dispersion not showing any bitter
taste, indicate the capability of precirol ato-05 used, both as taste masking agents.
Almost more than 90 percent of drug was released from the formulation within 1 h.
Further formulations were subjected to stability testing for 3 months at temperatures
25±5ºc/60±5%rh;  30±5ºc/65±5%rh  and  40±5ºc/75±5%rh.  Tablets  have  shown no
appreciable changes with respect to taste, disintegration, and dissolution profiles.
Ganesh kumar gudas et al,89. Study an attempt has been made to prepare
fast  dissolving  tablets  of  chlorpromazine  hcl  in  the  oral  cavity  with  enhanced
dissolution rate. The tablets were prepared with five superdisintegrants eg: sodium
starch  glycolate  ,  crospovidone ,croscarmellose,  l-hpc,  pregelatinised  starch  ,  the
blend  was  examined  for  angle  of  repose,  bulk  density,  tapped  density  ,
compressibility index and hausners ratio. The tablets were evaluated for hardness,
friability, disintegration time, dissolution rate, drug content, and were found to be
within 1 min. It was concluded that the fast dissolving tablets with proper hardness,
rapidly  disintegrating  with  enhanced  dissolution  can  be  made  using  selected
superdisintegrants.
Sradhanjali patra et al,  90 metronidazole is an antiemetic and prokinetic
drug used in the treatment of motion sickness in adults and children.as precision of
dosing and patient’s compliance become important prerequisite for quick relief from
motion  sickness,  there  is  a  need  to  develop  a  formulation  for  this  drug  which
overcomes  problems  such  as  difficulty  in  swallowing,  inconvenience  in
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administration while traveling and better compliance. Hence in the present research
work  mouth  dissolving  tablets  of  metronidazole  were  developed  with
superdisintegrants like crospovidone, indion 414, l – hpc and pregelatinised starch in
various  concentrations  like 8  % and  10 % w/w by wet  granulation  method.  All
formulations were evaluated for physical characteristics of compressed tablets such
as  weight  variation,  hardness,  friability,  drug content,  disintegration  time and  in
vitro  dissolution  study.  Among  all,  the  formulation  f4  (containing  10%  w/w
concentration of crospovidone) was considered to be the best formulation, having
disintegration time of 27 sec,  hardness 2.56 kg/cm2 and in vitro drug release of
92.23% in 15 min. All the formulation follows higuchi order release kinetics.
Prajapati et al, 91 carriedout the work on  piroxicam which  has bad taste,
half life of 30 hrs and poor water solubility.  In the present work to develop taste
masked orally disintegrating tablets of piroxicam, preformulation parameters  like
solubility,  particle  size,  tapped  density,  bulk  density,hausner  ratio,  carr’s
compressibility index, angle of repose, and differential scanning calorimetry study
were  performed.  Out  of  twelve  formulations  (f-1  to  f-12),  f-11  formulation
containing crospovidone xl 10 %, drug: polymer 1:0.35 , aspartame 6% and sodium
lauryl sulphate 0.5%, showed optimum characteristics of orodispersible tablet (odt)
of piroxicam with sufficient  crushing strength (5.5  to 6.5 kp),  friability (0.18%),
wetting time (28 sec) and disintegration time (22 sec). In-vitro dissolution profile
studies revealed that 82.3% drug was released within 5 min. The study concluded
that crospovidone xl and eudragit epo can successfully be used as superdisintegrant
and taste masking excipient respectively.
Pasupathi et.al,92.carried out the ork on lamotrigine chewable-dispersible
tablet was prepared by using crosspovidone xl10, as a disintegrating agent, different
grades of mannitol (pearlitol 160 c, pearlitol sd 200, pearlitol 500dc) as a diluents,
pvp k30 as a binder and carried out studies for weight variation, thickness, hardness,
content uniformity, disintegrating time, dispersion time, wetting time, in vitro drug
release  and  stability  study.  Tablets  were  prepared  by  using  direct  compression
method and wet granulation method. Furthermore, impact of different punches and
superdisintegrants  (sodium  starch  glycolate,  and  sodium  crosscarmalose)  were
carried on f16 formulation.
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Ashok Kumar et  al,93 investigation was to develop orally disintegrating
tablets of terbutaline sulphate. Granules containing drug, diluent, subliming agents,
aspartame were prepared by wet granulation technique using alcoholic solution of
polyvinyl  pyrrolidone K25 (10% w/v) as a binder.  The dried granules  were then
mixed  with  lubricant  magnesium  stearate  and  glidant  talc  and  compressed  into
tablets. Subliming agents was sublimed from the tablet by exposing it to drying at 65
0C. The tablets were evaluated for percentage friability, hardness, weight variation,
disintegration time and percentage drug content. Menthol containing tablets resulted
in rapid disintegration as compared with tablets containing ammonium bicarbonate
and camphor.  Formulations  F4  showed the minimum disintegration  time of  16s.
Formulations tested for all the official tests for tablets and were found to be within
limits.
Madhusudan  rao  Y  et  al,  94 deals  with  formulation  of  orodispersible
tablets (ODT) of buspirone that  disintegrate in the oral  cavity upon contact  with
saliva and thereby should improve therapeutic efficacy. The ODTs were prepared by
wet granulation and direct compression techniques. The optimized formulation was
also  prepared  by  freeze  drying  method.  The  influence  of  superdisintegrants,
crospovidone, croscarmellose sodium and sodium starch glycolate at three levels on
disintegration time, wetting time and water absorption ratio were studied. Tablets
were evaluated for weight and thickness variation, disintegration time, drug content,
in vitro dissolution, wetting time and water absorption ratio.
Pandey  Shivanand  et  al,95 development  of  taste  masked  orally
disintegrating  tablets  are  to  increase  patient  compliance,  ease  of  administration,
safety  and  appropriate  dosing.  Orally  disintegrating  formulations  also  provide
benefits  for pharmaceutical  companies  like lifecycle management,  line extension,
market expansion, cost effective drug development programs. This technology has
perceived faster onset of action (only if engineered for absorption in the oral cavity
or stomach) as the dosage form is disintegrated prior to reaching the stomach and is
ideal  for  acute  diseases  like  hypertension  and  heart  failure  and  particularly
applicable to manage breakthrough symptoms. Fast dissolving tablets (FDT), tablet
that disintegrates and dissolves rapidly in saliva without need of drinking water. The
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FDT usually dissolve in the oral cavity in about 10 seconds to 3 minutes. Faster the
drug goes into solution, the quicker absorption and onset of clinical effect.
PK Bhoyar et al,96  present work was to mask the taste of ondansetron
hydrochloride  and  to  formulate  its  patient-friendly  dosage  form.  Complexation
technique using indion 234 (polycyclic potassium with carboxylic functionality) and
an ion-exchange resin was used to mask the bitter taste and then the taste-masked
drug was formulated into an orodispersible tablet (ODT). The drug loading onto the
ion-exchange resin was optimized for mixing time, activation, effect of pH, mode of
mixing, ratio of drug to resin and temperature. The resinate was evaluated for taste
masking and characterized  by X-ray diffraction  study and  infrared  spectroscopy.
ODTs were formulated using the drug–resin complex. The developed tablets were
evaluated for hardness, friability, drug content, weight variation, content uniformity,
friability, water absorption ratio, in vitro and in vivo disintegration time and in vitro
drug release.  The tablets  disintegrated  in  vitro  and  in  vivo  within 24  and  27  s,
respectively. Drug release from the tablet was completed within 2 min. The obtained
results  revealed  that  ondansetron  HCl  has  been  successfully  taste  masked  and
formulated into an ODT as a suitable alternative to the conventional tablets.
Shailesh Sharma et al,97 formulate promethazine theoclate fast-dissolving
tablets that offer a suitable approach to the treatment of nausea and vomiting The
solubility  of  promethazine  theoclate  was  increased  by  formulating  it  as  a  fast-
dissolving tablet containing _-cyclodextrin, crospovidone, and camphor, using direct
compression  method.  A  33  full  factorial  design  was  used  to  investigate  the
combined  influence  of  three  independent  variables  –  amounts  of  camphor,
crospovidone and _-cyclodextrin - on disintegration time, friability and drug release
after 5 min. The optimization study, involving multiple regression analysis, revealed
that optimum amounts of camphor, crospovidone and _-cyclodextrin gave a rapidly
disintegrating/dissolving tablet. A Check point batch was also prepared to verify the
validity  of  the  evolved  mathematical  model.  The  optimized  tablet  should  be
prepared with an optimum amount of _-cyclodextrin (3.0 mg), camphor (3.2mg) and
crospovidone (2.61 mg) which disintegrated in 30 s, with a friability of 0.60 % and
drug release of 89 % in 5 min.
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OBJECTIVE OF THE STUDY
Oral  route  of  administration  still  has  potential,  as  most  preferred  route
because of its numerous advantages. The most popular oral dosage forms are tablets
and capsules. However, one important drawback of these dosage forms is the need
to swallow. Many patients express difficulty in swallowing tablets and hard gelatin
capsules, resulting in non-compliance and ineffective therapy. 
Recent  advances  in  Novel  Drug  Delivery  Systems  (NDDS)  aims  to
formulating a dosage form of drug molecules for convenient administration and to
achieve better patient compliance. One such approach leads to development of oral
disintegrating tablets.
Advantages  of  this  drug  delivery  system  include  convenience  of
administration and accurate dosing as compared to liquids, easy portability, ability
to provide advantages of liquid medication in the form of solid preparation, ideal for
pediatric and geriatric patients and rapid dissolution/absorption of the drug, which
may produce rapid onset of action. Some drugs are absorbed from mouth, pharynx
and  oesophagus  as  the  saliva  passes  down  into  the  stomach  and  in  such  cases
bioavailability of the drug is increased: pre-gastric absorption can result in improved
bioavailability  and  as  result  of  reduced  dosage,  improved  clinical  performance
through a reduction of unwanted effects.
A  solid  dosage  form that  dissolves  rapidly  in  oral  cavity,  resulting  in
solution or suspension without the need of water is known as oral dissolving tablets.
When this type of tablet is placed into the mouth, the saliva will serve to rapidly
dissolve  the  tablet.  They  are  also  known  as  oro-dissolving,  rapid  –  dissolve
orodispersible, melt in mouth, rapimelt, quick dissolving tablets. 
Conventional  oral  dosage  forms  like  tablets,  capsules  are  available  in
market but the major drawbacks with these are  many patients find it  difficult  to
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swallow (Dysphagia) tablets and hard gelatin capsules. The difficulty experienced in
particular by pediatrics and geriatrics  patients.  Other  groups that may experience
problems  include  the  mentally  ill,  mentally  disabled  and  patients  who  are
uncooperative and hence do not take their medicines as prescribed leading to patient
noncompliance. 
Fluoxetine Hydrochloride has been used for the treatment of anti pyscotic.
It  comes  under  BCS  class  4  i.e.,  low  solubility  and  low  permeability  and  has
biological  half  life  (24-72  days).  The  administration  of  conventional  tablet  to
psychotic patients is very difficult. Therefore need to develop suitable dosage form
like  Fluoxetine  oral  disintegrating  tablet  which  may  easy  to  administer  to  the
psychotic patients. 
The objective of this study is to design and development of fluoxetine oral
disintegrant  tablet  by  using  different  superdisintegrants  like  crospovidone,
croscarmellose sodium and sodium starch glycolate.  And also present work aims
that effect on diluents on disintegration power and in vitro dissolution of the tablets.
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PLAN OF WORK
The  present  work  was  carried  out  to  formulate  Oral  Disintegrating
Fluoxetine Hydrochloride tablets and to evaluate the invitro and stability studies for
the prepared Fluoxetine Hydrochloride tablets. It was planned to carry out this work
as outlined below.
 Characterization of drug substances and other excipients.
 Formulation  development  of  Fluoxetine  Hydrochloride  Orally
Disintegrating tablets by Direct Compression Technique. 
 Evaluation of the pre compressional parameters.
 To evaluate the formulated Fluoxetine Hydrochloride tablets for the
following parameters.
a) Tablet thickness.
b) Weight variation.
c) Tablet friability.
d) Wetting time.
e) Tablet hardness.
f) Assay 
g) Disintegration.
h) Dissolution
 To  carry  out  the  stability  studies  for  finalized  formula  of  Orally
Disintegrating  Fluoxetine  Hydrochloride  Tablet  as  per  ICH
guidelines.
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DRUG PROFILE 98,99,100
FLUOXETINE HYDROCHLORIDE
Category : Antidepressant agent 
Chemical Name : (RS)-N-methyl-3-phenyl-3-[4-
(trifluoromethyl)phenoxy]propan-1-amine
Description : A white to off white crystalline solid.
Molecular Structure
Molecular Formula : C17H18F3NO•HCL
Molecular weight : 345.79 
Bioavailability : 72%
Half life : 1-3 days (acute)
                                         4-6 days (chronic)
Solubility : Soluble  in  methanol  and  ethanol,  Sparingly  soluble  in
acetonitrile, chloroform and acetone & slightly soluble in
Dichloromethane, water and ethyl acetate.
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Uses
Fluoxetine  is  an  antidepressant  (selective  serotonin  reuptake  inhibitor-
SSRI) used to treat depression, obsessive-compulsive disorder(bothersome thoughts
that won’t go away and the need to perform certain actions over and over), some
eating disorders and panic attacks(sudden unexpected attacks of extreme fear and
worry  about  these  attacks).  It  is  used  to  relieve  the  symptoms  of  premenstrual
dysphoric  disorder,  including  mood swing,  irritability  and  bloating.  It  works  by
restoring  the  balance  of  certain  natural  substances  (neurotransmitters  such  as
serotonin) in the brain.  Fluoxetine may improve your  feelings  of  well-being and
energy level and decrease nervousness. 
CLINICAL PHARMACOLOGY
Mechanism of Action
Metabolized to norfluoxetine, fluoxetine is a selective serotonin-reuptake
inhibitor (SSRI), it blocks the reuptake of serotonin at the serotonin reuptake pump
of  the  neuronal  membrane,  enhancing  the  actions  of  serotonin  on
5HT1A autoreceptors.  SSRIs  bind  with  significantly  less  affinity  to  histamine,
acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Pharmacodynamics
Fluoxetine,  an antidepressant  agent  belonging to the selective serotonin
reuptake  inhibitors  (SSRIs),  is  used  to  treat  depression,  bulimia  nervosa,
premenstrual  dysphoric  disorder,  panic  disorder  and  post-traumatic  stress.
According to the amines hypothesis, a functional decrease in the activity of amines,
such  as  serotonin  and  norepinephrine,  would  result  in  depression;  a  functional
increase of the activity of these amines would result in mood elevation. Fluoxetine's
effects are thought to be associated with the inhibition of 5HT receptor, which leads
to an increase of serotonin level.
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Pharmacokinetics
The single-  and multiple-dose pharmacokinetics  of fluoxetine are linear
and dose-proportional  in a dose range of 10 to 40 mg/day.  Biotransformation of
fluoxetine  is  mainly  hepatic,  with  a  mean  terminal  half-life  of  about  1-3
days(acute),4-6  days(chronic).  With  once-daily  dosing,  steady  state  plasma
concentrations are achieved within approximately one week.
Absorption and Distribution
Following a single oral dose (10 mg tablet or solution) of fluoxetine, peak
blood levels occur at about 6-8 hours. Absorption of fluoxetine is not affected by
food.
The  absolute  bioavailability  of  fluoxetine  is  about  72%  relative  to  an
intravenous dose, and the volume of distribution of fluoxetine is about 20 L/kg. Data
specific on fluoxetine are unavailable.
The  binding  of  fluoxetine  to  human  plasma  proteins  is  approximately
94.5%.
Metabolism and Elimination
Limited  data  from animal  studies  suggest  that  fluoxetine  may undergo
first-pass metabolism may occur via the liver and/or lungs. Fluoxetine appears to be
extensively metabolized, likely in the liver, to norfluoxetine and other metabolites.
Norfluoxetine,  the  principal  active  metabolite,  is  formed  via N-demethylation  of
fluoxetine.  Norfluoxetine  appears  to  be  comparable  pharmacologic  potency  as
fluoxetine.  Fluoxetine  and  norfluoxetine  both  undergo  phase  II  glucuronidation
reactions in the liver. It is also thought that fluoxetine and norfluoxetine undergo O-
dealkylation  to  form p-trifluoromethylphenol,  which  is  then  subsequently
metabolized to hippuric acid.
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The  primary  route  of  elimination  appears  to  be  hepatic  metabolism to
inactive metabolites excreted by the kidney.
Marked formulations : Adofen , Fluctin, Fluoxeren, Prozac 
Table 6 - Drug Interactions
Cyclosporine The  antidepressant  increases  the  effect  and  toxicity  of
cyclosporine
Amphetamine Risk of serotoninergic syndrome
Phentermine Risk of serotoninergic syndrome
Tramadol The use of two serotonin modulators, such as fluoxetine and
tramadol,  may  increase  the  risk  of  serotonin  syndrome.
Fluoxetine may decrease the effect of tramadol by decreasing
active metabolite production.
Erythromycin Possible serotoninergic syndrome with this combination
Eletriptan Increased risk of CNS adverse effects
Ziprasidone Additive  QTc-prolonging  effects  may  increase  the  risk  of
severe arrhythmias. Concomitant therapy is contraindicated.
Phenytoin Fluoxetine increases the effect of phenytoin
Metoprolol The SSRI, fluoxetine, may increase the bradycardic effect of
the beta-blocker, metoprolol.
Dicumarol The  SSRI,  fluoxetine,  increases  the  effect  of  anticoagulant,
dicumarol.
Atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of
atomoxetine
Zolmitriptan Use  of  two  serotonin  modulators,  such  as  zolmitriptan  and
fluoxetine,  may  increase  the  risk  of  serotonin  syndrome.
Consider alternate therapy or monitor for serotonin syndrome
during concomitant therapy.
Dihydroergotamine Possible ergotism and severe ischemia with this combination
Dosage
Usual adult dose for anxiety
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10 mg orally once a day in the morning or evening with or without food.
The dose may be increased to 20 mg, after a minimum of one week.
Usual adult dose for depression
10 mg orally once a day in the morning or evening with or without food.
The dose may be increased to 20 mg, after a minimum of three weeks.
Usual pediatric dose for depression
12to17years
10 mg orally once a day in the morning or evening with or without food.
The dose may be increased to 20 mg, after a minimum of three weeks.
EXCIPIENTS PROFILE101,102
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MANNITOL
Synonyms : Cordycepic  acid,  Manna sugar,  D-mannite,
Mannitolum; Mannogem.
Chemical Name : D-Mannitol 
Empirical Formula : C6H14O6
Structural Formula
Molecular Weight : 182.17
Functional Category : Plasticizer, sweetening agent, tablet and capsule diluent.
Solubility 
Freely soluble in water,  soluble in alkaline solutions, slightly soluble in
pyridine, very slightly soluble in alcohol, practically insoluble in ether.
Applications in Pharmaceutical Formulation or Technology
Mannitol is widely used as a diluent (10–90% w/w) in tablet formulations,
since  it  is  not  hygroscopic  and may thus  be used with moisture  sensitive active
ingredients. It may be used in direct compression tablet applications, for which the
granular and spray dried forms are available, or in wet granulations. Granulations
containing mannitol have the advantage of being dried easily. It is commonly used
as an excipient in the manufacture of chewable tablet formulations and also used as
a diluent in rapidly dispersing oral dosage forms. 
Description
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It  occurs  as  a  white,  odourless,  crystalline  powder,  or  free  flowing
granules.  It  has  a  sweet  taste  and  imparts  a  cooling  sensation  in  the  mouth.
Microscopically, it appears as orthorhombic needles when crystallized from alcohol.
Incompatibilities
Mannitol solutions, 20% w/v or stronger, may be salted out by potassium
chloride or sodium chloride.(19) Precipitation has been reported to occur when a
25% w/v mannitol solution was allowed to contact plastic. Sodium cephapirin at 2
mg/mL  and  30  mg/mL  concentration  is  incompatible  with  20%  w/v  aqueous
mannitol  solution.  Mannitol  is  incompatible  with xylitol  infusion and  may form
complexes with some metals such as aluminum, copper, and iron. Reducing sugar
impurities  in  mannitol  have  been  implicated  in  the  oxidative  degradation  of  a
peptide in a lyophilized formation.
Safety 
Mannitol  is  a  naturally  occurring  sugar  alcohol  found  in  animals  and
plants; it is present in small quantities in almost all vegetables. Laxative effects may
occur if mannitol is consumed orally in large quantities. If it is used in foods as a
bodying  agent  and daily ingestion of over  20 g is  foreseeable,  the product  label
should bear the statement ‘excessive consumption may have a laxative effect’.
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CROSPOVIDONE
Synonyms
Crospovidonum,  Crospopharm,  crosslinked  povidone,  Kollidon  CL,
Kollidon CL-M, Polyplasdone XL, Polyplasdone XL-10, Polyvinyl polypyrrolidone.
Chemical Name : 1-Ethenyl-2-pyrrolidinone homopolymer
Empirical Formula 
and Molecular Weight : (C6H9NO)n >1000000
                            
Functional Category : Tablet disintegrant
Solubility 
Practically insoluble in water and in most common organic solvents.
Applications in Pharmaceutical Formulation or Technology
Crospovidone is a water insoluble tablet disintegrant and dissolution agent
used in tablets prepared by direct compression or wet and dry granulation methods.
It can also be used as a solubility enhancer. Crospovidone can be used to enhance
the solubility of poorly soluble drugs. 
Description
Crospovidone is  a white  to  creamy white,  finely divided,  free  flowing,
practically tasteless, odourless, hygroscopic powder.
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Incompatibilities
Crospovidone  is  compatible  with  most  organic  and  inorganic
pharmaceutical ingredients. When exposed to a high water level
Stability and Storage Conditions
Since  crospovidone  is  hygroscopic,  it  should  be  stored  in  an  airtight
container in a cool, dry place.
ASPARTAME 
Synonyms
Aspartamum,  Aspartyl  phenylamine  methyl ester,  Natra  Taste,
NutraSweet, Pal Sweet, Pal Sweet Diet.
Chemical Name : N-L-a-Aspartyl-L-phenylalanine 1-methyl ester 
Empirical Formula 
and Molecular weight : C14H18N2O5; 294.30
Molecular Structure
                      
Functional category : Sweetening agent.
Solubility
It is slightly soluble in ethanol (95%), sparingly soluble in water.
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Applications in Pharmaceutical Formulation or Technology 
It  is used as a  sweetening agent  in tablets,  powder mixes,  and vitamin
preparations. The approximate sweetening power is 180–200 times that of sucrose.
Unlike some other intense sweeteners,  aspartame is metabolized in the body and
consequently has some nutritive value: 1 g provides approximately 17 kJ (4 kcal).
Description
It  occurs  as  an off  white,  almost  odourless  crystalline  powder  with an
intensely sweet taste.
EUDRAGIT EPO
Synonyms : Methacrylic acid, eudragit.
Srtucture            :
For Eudragit EPO
R1, R3 = CH3
R2  = CH2CH2N(CH3)2
R4 = CH3, C4H9
Chemical Name : Poly(butyl methacylate-co-(2-dimethylaminoethyl)   
                   methacrylate-co-methyl methacrylate) 1:2:1
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Description
It is a white powder with a characteristic amine-like odour.
Characteristics
It shows low viscosity, high pigment binding capacity, Good adhesion.
Functional Category
Film forming agent, tablet binder, tablet diluents, Taste masking agent,
Glass Transition Temperatur (Tg) : ~48°C
Solubility :  Soluble in gastric fluid up to pH 5.0
Typical Properties : Bulk density       : 0.390 g/cm3
Tapped density   : 0.424 g/cm3
Applications in Pharmaceutical Formulation or Technology:
Used as  a  plain  or  insulating film former.  It  is  soluble  in  gastric  fluid
below pH 5.
Stability and Storage Conditions
Dry powder  polymer  forms  are  stable  at  temperatures  less  than  308C.
Above this temperature, powders tend to form clumps, although this does not affect
the quality of the substance and the clumps can be readily broken up. Dry powders
are stable for at least 3 years if stored in a tightly closed container at less than 308C.
Dispersions are sensitive to extreme temperatures and phase separation occurs below
08C. Dispersions should therefore be stored at temperatures between 5 and 258C
and  are  stable  for  at  least  18  months  after  shipping  from  the  manufacturer’s
warehouse if stored in a tightly closed container at the above conditions.
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Incompatability
Incompatibilities  occur  with  certain  polymethacrylate  dispersions
depending upon the ionic and physical properties of the polymer and solvent. For
example,  coagulation  may be  caused  by  soluble  electrolytes,  pH changes,  some
organic  solvents,  and  extremes  of  temperature;  Interactions  between
polymethacrylates and some drugs can occur, although solid polymethacrylates and
organic solutions are generally more compatible than aqueous dispersions.
Handling Precautions
Observe normal precautions appropriate to the circumstances and quantity
of material handled. Additional measures should be taken when handling organic
solutions of polymethacrylates. Eye protection, gloves, and a dust mask or respirator
are  recommended.  Polymethacrylates  should  be  handled  in  a  well-ventilated
environment and measures should be taken to prevent dust formation. Acute and
chronic  adverse  effects  have  been  observed  in  workers  handling  the  related
substances methyl methacrylate and poly- (methyl methacrylate) (PMMA).
SODIUM STARCH GLYCOLATE (SSG)
Synonyms
Carboxymethyl starch, Explotab, Primojel.
Functional Category
Tablet and capsule disintegrant. 
Description 
It is white to off-white, odourless, tasteless, free-flowing powder.
Solubility
It is practically insoluble in water; sparingly soluble in ethanol (95%). In
water it swells upto 300 times its volume. 
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Incompatibilities
Incompatible with ascorbic acid 
Stability and Storage
It  is  a stable material.  It  should be stored in a well closed container  to
protect from wide variations in humidity and temperature that may cause cracking.
Safety
It is generally regarded as a non-toxic and non-irritant material. However,
oral ingestion of large quantities may be harmful. 
Applications in Pharmaceutical Formulation and Technology
As a disintegrant in tablet (wet granulation and direct compression) and
capsule formulation in 2-8% concentration. 
Sodium lauryl sulfate
Synonyms
Dodecyl  sodium  sulfate;  Elfan  240;  sodium  dodecyl  sulfate;  sodium
laurilsulfate; sodium monododecyl sulfate; sodium monolauryl sulfate; Texapon K12P. 
Structure
Chemical name :  Sulfuric acid monododecyl ester sodium salt.
Empirical formula : C12H25NaO4S
Molecular weight :  288.38
Functional category :
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Anionic surfactant; detergent; emulsifying agent; skin penetrant; tablet and
capsule lubricant; wetting agent.
Applications in Pharmaceutical Formulation and Technology:
Sodium lauryl sulfate is an anionic surfactant employed in a wide range of
non-parenteral  pharmaceutical  formulations  like  anionic  emulsifier,  forms  self-
emulsifying  bases  with  fatty  alcohols  in  concentrations  (0.5-2.5%),  as  a  skin
cleanser in topical applications (1%), as a tablet lubricant (1–2%), as a wetting agent
in dentifrices (1-2%).
Description
Sodium lauryl  sulfate consists of white or cream to pale yellow colored
crystals, flakes, or powder having a smooth feel, a soapy, bitter taste, and a faint
odor of fatty substances.
Melting point   : 204–207o C (for pure substance).
Solubility :
Freely soluble in water, giving an opalescent solution; practically insoluble
in chloroform and ether.
Stability and storage conditions
Sodium lauryl sulfate is stable under normal storage conditions. However,
in solution, under extreme conditions, i.e., pH 2.5 or below, it undergoes hydrolysis
to lauryl alcohol and sodium bisulfate. The bulk material should be stored in a well-
closed container away from strong oxidizing agents in a cool, dry place.
Incompatibilities
Sodium  lauryl  sulfate  reacts  with  cationic  surfactants,  causing  loss  of
activity even in concentrations too low to cause precipitation Solutions of sodium
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lauryl sulfate (pH 9.5–10.0) are mildly corrosive to mild steel, copper, brass, bronze,
and aluminum. Sodium lauryl sulfate is also incompatible with some alkaloidal salts
and precipitates with lead and potassium salts.
CROSCARMELLOSE SODIUM (CCS)
Synonyms
Cross-linked  carboxy  methylcellulose  sodium,  Primellose,  Solutab  and
Ac-Di-Sol
Functional category  : Tablet and capsule disintegrant.  
Description   :  Odorless and white coloured powder
Solubility :  
It is insoluble in water. Although croscarmellose sodium rapidly swells to
4-8 times of its original volume on contact with water.
Incompatibilities
The  efficacy  of  disintegrants,  such  as  Croscarmellose  sodium,  may be
slightly  reduced  in  tablet  formulations  prepared  by  wet  granulation  or  direct
compression process which contain hygroscopic material such as sorbitol.
Stability and storage
Croscarmellose sodium is a stable though hygroscopic material. A model
tablet formulation prepared by direct compression, with Croscarmellose sodium as
disintegrant,  showed no significant difference in drug dissolution after  storage at
300C for 14 months
Safety
Croscarmellose  is  mainly used as  a  disintegrant  in  oral  pharmaceutical
formulations and is  generally regarded  as  an essentially nontoxic and nonirritant
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material.  However,  oral  consumption of  large  amount  of  Croscarmellose sodium
may have a laxative effect although the quantities used in solid dosage formulations
are unlikely to cause such problems. .
Applications in pharmaceutical formulation and technology
Croscarmellose is used as a Superdisintegrant in capsules around 10-25%
and also used in tablets  between 0.5-5%
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MATERIALS AND METHODS
LIST OF EQUIPMENTS
Table -7 List of Equipments used
Equipment Manufacturer Model
Electronic single pan balance Sartorius Essae LA1205 TE2145
Mechanical Sifter with sieve 40 and 60 Retsec AS100
Tapped Density apparatus Electro lab ETD 1020
LOD Satorious MAB5
Analytical Sieve Shaker Retsec AS200
Blender Rimec 410AG
Compression Machin Chamundi Pharma 
Machinery
PPM406300210
Friabilator Electro lab Ef-2
Dissolution Apparatus Electro lab TDTO8L
Ultra voilet-visible spectroscopy Shimadzu UV 2400PC 
series
Disintegration Apparatus Electro Lab ED2AL
Moisture analyzer Sartorius ---
pH meter Eutech cyber scan 
100
---
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LIST OF CHEMICALS
Table 8 - List of Chemicals used
Ingredients Supplier
Fluoxetine hydrochloride Merck Pvt.Ltd
CrosPovidone CL-F Merck Pvt.Ltd
Eudrogit Epo Merck Pvt.Ltd
Croscarmolose sodium Merck Pvt.Ltd
Sodium Starch Glycolate Merck Pvt.Ltd
Aspartame Merck Pvt.Ltd
Microcrystalline cellulose Merck Pvt.Ltd
Mannitol SD200 (Peritol) Merck Pvt.Ltd
Sodium Lauryl sulfate Merck Pvt.Ltd
Peppermint flavour  Merck Pvt.Ltd
Aerosil Merck Pvt.Ltd
Talc Merck Pvt.Ltd
7.1 PREFORMULATION STUDIES  
Standard calibration curve of the Fluoxetine Hydrochloride 
10mg of the dug was dissolved in the 50ml of methanol and sonicated for
few minutes and further diluted to 100ml with methanol. From this above solution
further dilutions were carried out to obtained 5, 10, 15, 20, 25 µg/ml using methanol.
The  absorbance  of  the  above  concentration  was  measured  at  226nm using  UV
spectroscopy.
Bulk Density1
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It’s a measurement to describe packing of particles. Bulk density/apparent
density is used to determine the amount of drug that occupies the volume (gm/ml).
Determination of Bulk density
Weighed  accurately  the  quantity  of  blend  was  transferred  into  100  ml
measuring cylinder  without tapping during transfer.  The volume occupied by the
drug was measured. Bulk density was measured by using formula ρb = m / Vb.  The
results were shown in the table-15.
Tapped density103
Powder blend was taken in 100 ml measuring cylinder that was placed in
Electro  lab tapped  density  apparatus  (method USP-I).  Initial  volume (V0)  of  the
cylinder was noted and then the cylinder was  tapped 250 times and volume was
measured. Then further an additional 500 tapings were repeated. No difference was
noted between the volumes of the two tapings (250 and 500). The final volume (V)
was  considered  after  completion of  500 taps.   Tapped density was measured by
using formula ρt = m / Vt. The results were shown  in the table-15.
Compressibility Index103,104
Powder blend was transferred to 100ml-graduated cylinder and subjected
to 250 & 500taps in tap density tester (Electro lab). The difference between two taps
should be less than 2%. The % of compressibility index calculated using formula 
Compressibility Index = 100 * (ρtapped -ρbulk) / ρtapped
Hausner’s ratio103
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It  is  measurement  of  frictional  resistance  of  the  drug.  The ideal  range
should be 1.2 –1.5. It is determined by ratio of tapped density and bulk density.
Hausners ratio = ρtapped / ρbulk
Table 9 - Scale of Flowability
Compressibility index (%) Flow character Hausner Ratio
≤10 Excellent 1.00 – 1.11
11 – 15 Good 1.12 – 1.18
16 – 20 Fair 1.19 – 1.25
21 – 25 Passable 1.26 – 1.34
26 – 31 Poor 1.35 – 1.45
32 – 37 Very poor 1.46 – 1.59
>38 Very, very poor >1.60
Angle of repose103
It is defined as the maximum angle that can be obtained between the free
standing of powder heap and horizontal plane, angle of repose calculated by using
given formula
Angle of  repose = 1 heigh of thepiletan
radius of thepile
- æ ö
ç ÷
è ø
Procedure
Powder blend was passed through a funnel kept at a height 2 cm from the
base. The powder passed till it forms a heap and touches the tip of the funnel. The
radius was measured and angle of repose was calculated by using the above formula.
Table -10 Flow Properties and Corresponding Angle of Repose
Flow Property Angle of Repose (degrees)
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Excellent 25 – 30
Good 31 – 35
Fair – aid not needed 36 – 40
Passable – may hang up 41 – 45
Poor - must agitate, vibrate 46 – 55
Very poor 56 – 65
Very, very poor >66
From the above results it is evident that the drug has poor flow properties,
as the compressibility index, Hausner’s ratio and Angle of repose values are high. 
Melting point: melting point was carried by capillary tube method.
DRUG-EXCIPIENT COMPATIBILITY STUDIES
Drug-Excipient  compatibility studies  lay the foundation for  designing a
chemically  stable  formulation  for  clinical  and  commercial  development.  Drug
excipient  compatibility studies  are  conducted during preformulation to select  the
most appropriate excipients.
The  compatibility  studies  were  performed  between  Fluoxetine
hydrochloride and excipients with different ratios as given in Table 10. 
Table-11 Compatibility Study Ratio for Solid Dosage Forms
S.NO Ingredients Ratio
1 Fluoxetine Hydrochloride 
2 Fluoxetine Hydrochloride  + Eudragit EPO 1:1
3 Fluoxetine Hydrochloride  + Crospovidone CL-F 1:0.5
4 Fluoxetine Hydrochloride  + croscarmolse sodium 1:0.5
5 Fluoxetine Hydrochloride  + Aspartame 1:0.5
6 Fluoxetine Hydrochloride  + sodium starch glycolate 1:0.5
7 Fluoxetine Hydrochloride  + micro crystalline cellulose 1:10
8 Fluoxetine Hydrochloride  + mannitol 1:10
9 Fluoxetine Hydrochloride  + Aerosil 1:0.05
10 Fluoxetine Hydrochloride  + sodium lauryl sulfate 1:0.1
11 Fluoxetine Hydrochloride  + peppermint flavour 1:0.05
12 Fluoxetine Hydrochloride  + Talc 1:0.05
The active ingredients and the excipients were mixed in the selected ratios
using a mortor and pestle. The mixtures was transferred into glass vials and sealed.
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The samples were placed as first set of initial samples and second set of samples
were kept at 40°C±2°C/75%±5 % RH for 4 weeks. The samples were analyzed by
IR and DSC analysis. 
7.2 MANUFACTURING PROCESS 
Formulation of oral disintegrating tablets of Fluoxetine Hydrochloride 10
mg was carried out by direct compression technique. Eudragit EPO was melted at
70°C and then Fluoxetine Hydrochloride was added and continued stirring for 5 min
then the blend was cooled and passed through 80# mesh. Other excipients passed
through 40# mesh and added to drug and Eudragit  mixture.  The final blend was
mixed  thoroughly  and  compressed  with  6mm  flat  bowled  edge  punch.  The
composition of different formulation was shown in the table-12.
Table-12 Formulation Developmental Trails
 Excipients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9
Fluoxetine Hydrochloride 10 10 10 10 10 10 10 10 10
Eydragit Epo 10 10 10 10 10 10 10 10 10
Croscarmolose sodium 5 5 5 0 0 0 0 0 0
Sodium starch glycolate 0 0 0 5 5 5 0 0 0
Crospovidone 0 0 0 0 0 0 5 5 5
Micro crystalline cellulose 68 34 0 68 34 0 68 34 0
Mannitol 0 34 68 0 34 68 0 34 68
Aspartame 5 5 5 5 5 5 5 5 5
Aerosil 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Sodium lauryl sulfate 1 1 1 1 1 1 1 1 1
Peppermint flavour 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Talc 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
Total weight(mg) 100 100 100 100 100 100 100 100 100
7.3 POST COMPRESSION PARAMETERS
PHYSICAL APPEARANCE 
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The  physical  appearance  of  the  compressed  tablets  involves  the
measurement  of  a  number  of  attributes  like  tablet  shape,  smoothness,  chipping,
cracks, surface texture, colour etc.
THICKNESS 
Thickness was determined for 20 pre-weighed tablets of each batch using a
digital vernier scale and the average thickness was determined in mm.  The tablet
thickness should be controlled within a ± 5% variation of a standard.
WEIGHT VARIATION 
20 tablets  were  selected  randomly from a  batch  and  were  individually
weighed  and then the average  weight  was  calculated.  The tablets  meet  the USP
specifications if not more than 2 tablets are outside the percentage limit and if no
tablet differs by more than 2 times the percentage limits.
HARDNESS TEST
The crushing load which is the force required to break the tablet in the
radial direction was measured using a Schluenzier hardness tester. The hardness of
10 tablets was noted and the average hardness was calculated. It is given in kp or
kg/cm2. 
PERCENTAGE FRIABILITY
In friability testing the tablets are subjected to abrasion and shock. It gives
an  indication  of  the  tablets  ability  to  resist  chipping  and  abrasion  during
transportation and shipping. 
Method 
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10  tablets  were  taken  and  initial  weight  was  noted.  The  tablets  were
rotated in the Roche Friabilator  for  100 revolutions at  25 rpm. The tablets were
dedusted and reweighed. 
The  percentage  friability  is  expressed  as  the  loss  of  weight  and  is
calculated by the formula:
The percentage friability should be not more than 1%w/w of the tablets
being tested.
DISINTEGRATION TIME
Disintegration time is the time taken by the tablet to breakup into smaller
particles. The disintegration test was carried out in an apparatus containing a basket
rack assembly with six glass tubes of 7.75 cm in length and 2.15 mm in diameter,
the bottom of which consists of a #10 mesh sieve. The basket is raised and lowered
28-32 times per minute in a medium of 900 ml which is maintained at 37±20C. Six
tablets were placed in each of the tubes and the time required for complete passage
of tablet fragments through the mesh (# 10) was considered as the disintegration
time  of  the  tablet.  The  disintegration  time  that  patients  can  experience  for  oral
disintegrating tablets ranges from 5 to 30seconds.
WETTING TIME
Wetting time of dosage form is related to with the contact angle. Wetting
time of the ODT is another important parameter, which needs to be assessed to give
an insight into the disintegration properties of the tablet. Lower wetting time implies
a  quicker  disintegration  of  the  tablet.  The  wetting  time  of  the  tablets  can  be
measured  by  using  the  simple  procedure73.  Five  circular  tissue  papers  of  10cm
diameter was placed in a petridish. Ten milliliters of water soluble dye solution is
added to petridish. A tablet was carefully placed on the surface of the tissue paper.
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The time required for water to reach upper surface of the tablet was noted as the
wetting time. For measuring water absorption ration the weight of the tablet before
keeping in the petridish is noted (Wb). The wetted tablet from the petridish is taken
and reweighed (Wa). The water absorption ratioR, can be the determined according
to the following equation.
R = 100 (Wa-Wb) / Wb
                                                                                         
                               Figure 10 Illustration of wetting time
DISSOLUTION STUDIES
Dissolution is a process by which the disintegrated solid solute enters the
solution. The test determines the time required for a definite percentage of the drug
in a tablet to dissolve under specified conditions.
Method
The dissolution test was carried out in USP Apparatus Type II (paddle)
with 1000ml of 1.2 pH as the dissolution medium. The samples were drawn at 5, 10,
15, 30 and 45 min. Fresh volume of the medium were replaced with the withdrawn
volume to maintain the sink conditions. Samples withdrawn and were analyzed for
the percentage of drug released.
Dissolution Parameters
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Dissolution Apparatus : USP Apparatus Type II (Paddle)
Dissolution Medium : 0.1 M Hcl
Volume                         : 1000 ml
Temperature                : 37±2° C
 Rpm                               : 100   
Sampling Intervals (min) : 5, 10, 15,30and 45min
CONTENT UNIFORMITY
About  12  tablets  were  grinded  to  fine  powder  in  a  dry  mortar  and  a
quantity  of  powder  equavalent  to  100mg  of  Fluoxetine  Hydrochloride   was
transferred into 100ml volumetric flask. To this 50ml of methanol was added and
sonicated  to  dissolve  the  drug  and  diluted  to  volume with methanol  and  mixed
thoroughly. The solution was filtered through what man filter paper no 1.and futher
diluted to get a requied ppm
UV parameters
Instrument Type : UV – 2400PC series
Measuring mode : Absorbance
Wavelength range : 200.00nm to 300.00nm
Scan speed : Medium
Slit width : 2.0nm
Calculation
STABILITY STUDIES
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The purpose of stability testing is to provide evidence on how the quality
of a drug substance or drug product varies with time under the influence of a variety
of environmental factors, such as temperature, humidity etc.
Accelerated study studies of the product was carried out at 40°C±2°C/75%
±5% RH for 2 months. The samples were analysed drug content, hardness, friability
and disintegration time, dissolution.
                              
                               
82
RESULTS AND DISCUSSION
STANDARD CALIBRATION CURVE
Table13- Standard Calibration Curve of the Fluoxetine Hydrochloride
Concentration(µg/ml) Absorbance at 228nm
0 0
5 0.196
10 0.370
15 0.591
20 0.81
25 0.985
Slope(m) 0.0395
Intercept 0.003
correlation 0.9985
           
Figure-11  Standard calibration curve of the Fluoxetine Hydrochloride
Table -14 Raw Material Analysis of the Fluoxetine Hydrochloride Drug
TEST SPECIFICATION RESULT
Description A white to half white crystalline solid A white crystalline
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solid
Melting point
(0 C)
Between 179-182 180.5to 183.9
Solubility
Soluble in methanol and ethanol,
sparingly soluble in acetonitrile,
chloroform and acetone and slightly
soluble in dichloromethane and ethyl
acetate
Compiles
Assay (%) NLT 98.0%& NMT 102.0% 99.7%
Raw Material analysis of Fluoxetine Hydrochloride
The raw material analysis of the Fluoxetine Hydrochloride was carried out
and  the results were shown in table 14. 
Table-15 Flow Properties of Fluoxetine Hydrochloride
S.NO TEST RESULT
1 Bulk density(g/ml) 0.238
2 Tap density(g/ml) 0.374
3 Compressibility Index (%) 36%
4 Hausner Ratio 1.57
5 Angle of Repose 48.71
        The results indicate that flow property of the drug was found very poor.
CHARECTERISATION OF PREFORMULATION BLEND
Table-15   Results of Pre Compression Parameters
BATCH NOS F1 F2 F3 F4 F5 F6 F7 F8 F9
Angle of repose 29.78 28.22 27.13 30.91 29.06 28.01 28.98 28.74 27.58
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Bulk density 0.629 0.601 0.584 0.487 0.526 0.599 0.564 0.571 0.586
Tap density 0.728 0.697 0.651 0.590 0.610 0.680 0.659 0.667 0.662
Compressibility index 13.59 13.77 10.29 17.45 13.77 11.91 14.41 14.39 11.48
Hausner’s ratio 1.21 1.15 1.11 1.21 1.15 1.13 1.17 1.16 1.13
The  flow property  of  blend  was  determined  by Angle  of  repose,  Bulk
Density, Tap Density, Compressability Index and Hauser’s ratio. The results were
shown in Table-14 and 15.  It  indicates  that  flow property of  powder blend was
increased after addition of excipients such as mannitol, crospovidone. 
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DRUG-EXCIPIENT COMPATIBILITY STUDIES
a) PHYSICAL OBSERVATION
Table-16 Physical Observation of Drug and Excipients
S.no Ingredient Ratio Description
Initial Final
40°C±2°C/75%±5
I
week
II
week
III
week
IV
week
1 Fluoxetine
Hydrochloride
White  to  half  white
crystalline solid
NC NC NC NC
2 Fluoxetine
Hydrochloride  +
Eudragit Epo
1:1 White  to  half  white
crystalline powder
NC NC NC NC
3 Fluoxetine
Hydrochloride  +
Crospovidone  CL-
F
1:0.5 White  to  half  white
crystalline powder
NC NC NC NC
4 Fluoxetine
Hydrochloride  +
croscarmolose
sodium
1:0.5 White  to  half  white
crystalline powder
NC NC NC NC
5 Fluoxetine
Hydrochloride  +
sodium  starch
glycolate
1:0.5 White  to  half  white
crystalline powder
NC NC NC NC
6 Fluoxetine
Hydrochloride  +
Aspartame
1:0.5 White  to  half  white
crystalline powder
NC NC NC NC
7 Fluoxetine
Hydrochloride  +
mannitol
1:10 White  to  half  white
amorphous powder
NC NC NC NC
8 Fluoxetine
Hydrochloride  +
micro  crystalline
cellulose
1:10 white  amorphous  powder NC NC NC NC
9 Fluoxetine
Hydrochloride  +
Aerosil
1:0.5 White  to  half  white
crystalline powder
NC NC NC NC
10 Fluoxetine
Hydrochloride  +
sodium  lauryl
sulfate
1:0.1 White crystalline powder NC NC NC NC
11 Fluoxetine
Hydrochloride  +
peppermint flavour
1:0.05 White coloured powder NC NC NC NC
12 Fluoxetine
Hydrochloride  +
Talc
1:0.05 White  to  half  white
crystalline powder
NC NC NC NC
NC-No change observed 
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B) FTIR ANALYSIS OF DRUG AND EUDRAGIT EPO
IR SPECTRUM OF FLUOXETINE HYDROCHLORIDE
                               Figure 12 FTIR of fluoxetine hydrchloride
IR SPECTROSCOPY OF FLUOXETINE AND EUDRAGIT EPO
Figure 13 FTIR of Fluoxetine and Eudragit EPO
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C) DSC ANALYSIS OF DRUG AND EUDRAGIT EPO
DSC OF FLUOXETINE HYDROCHLORIDE
Figure 14 DSC of Fluoxetine Hydrochloride
DSC OF DRUG AND EUDRAGIT EPO
Figure 15  DSC of Drug and Eudargit EPO
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The results of physical observation were given in the table 16. The results
indicate that there is no physical properties change in the drug and excipients. 
FTIR spectra of Fluoxetine Hydrohloride showed peaks at 1658, 1528, and
1345cm-1. Spectrum of drug + Eudragit EPO showed peaks at 1645, 1526 and 1345
cm-1. The results indicate that there is no interactions between the drug and Eudragit
EPO. DSC analysis of fluoxetine shown a single sharp exothermic effect  Tpeak =
165.68 ºC and ∆Ht = 90.8641 J/g. thermogram of drug and Eudragit EPO mixture
were shown a single exothermic peak Tpeak = 166.52º C and ∆Ht = 90.4141 J/g.
There is no change in exotherm of pure drug of fluoxetine in drug and Eudragit EPO
mixture. The results indicate that drug and Eudragit EPO are compatible.
POST COMPRESSION PARAMETERS
Table-17 Results of Post-Compressional Parameters
Physical Appearance  :- white colored tablets without  break line 
Formulat
ion Code
Avera
ge
weigh
t (mg)
±7.5
%
Thickn
ess
(mm)
±5%
Hardn
ess
(kp)
Percent
age
Friabilit
y (%)
0.1-
0.9%
In vitro
Disintegra
tion Time
(sec)
(±3)
Wetti
ng
time
(sec)
(±3)
Content
uniform
ity
F1 101 2.85 3.1 0.31 62 68 89.24%
F2 99.6 2.84 3.1 0.20 59 64 90.47%
F3 101.5 2.73 3.5 0.17 58 56 92.25%
F4 100 2.81 3 0.60 69 72 82.14%
F5 98.5 2.85 3.1 0.34 66 69 83.35%
F6 102.1 2.89 3.4 0.24 64 62 85.9%
F7 100 2.87 3.1 0.21 17 19 96.84%
F8 100 2.91 3.4 0.13 15 16 97.25%
F9 100 2.90 3.5 0.09 13 12 99.14%
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Disintegration time
Results of disintegration time were shown in Table 17. F9 formulation was
showed quick dissolution time of 13  (±3) sec.  Result  indicate  that  mannitol  and
Superdisintegrant crospovidone was increased disintegration time of the tablets.  
Wetting time
Wetting time of the formulation is shown in Table 17. The results indicate
that F9  showed  very  less  wetting  time  (12±3  sec). Reason  could  be
Superdisintegrant crospovidone was increased porous structure in the tablets.
in vitro DISSOLUTION STUDY
TABLE-18 In  vitro Dissolution  Study  of  Fluoxetine  Hydrochloride  Oral
Disintegrating Tablets
Cumulative percentage of drug release (%)
Time
(min) F 1 F 2 F 3 F4 F5 F6 F7 F 8 F9
0 0 0 0 0 0 0 0 0 0
5 25.13 25.79 26.61 16.23 21.28 24.86 31.76 33.12 36.25
10 48.41 49.37 55.71 36.49 37.14 41.62 57.65 57.54 61.04
15 77.49 78.12 81.72 70.33 72.59 74.2 81.51 83.29 87.71
30 84.35 85.14 88.27 78.47 80.02 82.52 89.75 89.79 93.26
45 89.24 90.47 92.25 82.14 83.35 85.9 96.84 97.25 99.14
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Figure 12 in  vitro Dissolution  study  of  Fluoxetine  Hydrochloride  Oral
Disintegrating Tablet
In vitro Dissolution study
In vitro dissolution profiles of the all formulations were shown in Table
17. Formulation F9 was showed maximum drug release  99.14% in 45 min. The
reason could be the formulations contains superdisintegrant crospovidone (5%), it
can provide more porous structure and water wicking capacity in the tablets.
STABILITY STUDIES
RESULTS OF STABILITY DATA
Table: 19 Stability Study Data
PARAMETERS
TESTED
STORAGE CONDITIONS
INITIAL
400C±20C / 75% ±5%
RH
1st month 2nd month
Description White colored round tablet
with out break line No change No change
Average weight (mg) 101 101 101
Thickness (mm) 2.87 2.87 2.86
Hardness (kp) 3.5 3.5 3.3
% Friability 0.09 0.12 0.17
Disintegration time (sec) 15 18 20
Assay 99.7 99.8 99.5
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Table-20 Dissolution  Data  of  Stability  Study  Sample(  Percentage  of  Drug
Release)
Time
Interval
(min)
Initial
400C±20C / 75% ±5% RH
Ist month
2nd month
0 0 0 0
5 36.25 36.71 35.78
10 61.04 61.29 60.81
15 87.71 87.91 87.12
30 93.26 93.12 91.98
45 99.14 99.01 98.72
Stability data of fluoxetine orodispersible tablets were shown in Table 19.
Stability study is conducted for the optimized formulation F9. The results indicate
that there is no change in the formulation after two months at 40◦C/75%RH. 
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CONCLUSION
Fluoxetine  HCL  orodispersible  tablet  was  developed  by  using  various
superdisintegrant.  Formulation contains crospovidone and mannitol showed quick
disintegration behavior. In vitro release profile indicates that formulation F9 showed
better  release  of  drug.  It  is  concluded  from  the  above  study  that  5%w/w
crospovidone  as  Superdisintegrant  and  mannitol  as  filler  most  suitable  for
preparation of fluoxetine Hydrochloride oral disintegrating tablet. 
Short  term  stability  study  of  Fluoxetine  Hydrochloride  orally
disintegrating tablet was carried out for 2 month at 40◦C/75%RH. Results of stability
study revealed that no change was observed in formulation throughout the stability
study. It can be concluded that fluoxetine hcl orodispersible tablet may have good
shelf life.
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